<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Discov Oncol</journal-id><journal-id journal-id-type="iso-abbrev">Discov Oncol</journal-id><journal-id journal-id-type="pmc-domain-id">4139</journal-id><journal-id journal-id-type="pmc-domain">discon</journal-id><journal-title-group><journal-title>Discover Oncology</journal-title></journal-title-group><issn pub-type="epub">2730-6011</issn><publisher><publisher-name>Springer</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12474789</article-id><article-id pub-id-type="pmcid-ver">PMC12474789.1</article-id><article-id pub-id-type="pmcaid">12474789</article-id><article-id pub-id-type="pmcaiid">12474789</article-id><article-id pub-id-type="pmid">41003869</article-id><article-id pub-id-type="doi">10.1007/s12672-025-03263-y</article-id><article-id pub-id-type="publisher-id">3263</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>hsa-miR-21-5p can serve as a standard biomarker in clear cell renal cell carcinoma by promoting tumor progression and influencing immune evasion</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Xu</surname><given-names initials="MY">Mu-Yang</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Wang</surname><given-names initials="X">Xu</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Yue</surname><given-names initials="SY">Shao-yu</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Meng</surname><given-names initials="QW">Qing-Wei</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bai</surname><given-names initials="XX">Xiao-Xin</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chen</surname><given-names initials="L">Lei</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="RR">Rong-Rong</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="K">Ke</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Xu</surname><given-names initials="LF">Ling-Fan</given-names></name><address><email>ayfyxlf@163.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Guan</surname><given-names initials="Y">Yu</given-names></name><address><email>guanyu928@126.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Liang</surname><given-names initials="CZ">Chao-Zhao</given-names></name><address><email>ayfymw@163.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03xb04968</institution-id><institution-id institution-id-type="GRID">grid.186775.a</institution-id><institution-id institution-id-type="ISNI">0000 0000 9490 772X</institution-id><institution>Department of Urology, </institution><institution>The First Affiliated Hospital of Anhui Medical University, Anhui Medical University, </institution></institution-wrap>No. 218 Jixi Road, Hefei, 230022 Anhui P.R. China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03xb04968</institution-id><institution-id institution-id-type="GRID">grid.186775.a</institution-id><institution-id institution-id-type="ISNI">0000 0000 9490 772X</institution-id><institution>Institute of Urology, </institution><institution>Anhui Medical University, </institution></institution-wrap>Hefei, Anhui P.R. China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03xb04968</institution-id><institution-id institution-id-type="GRID">grid.186775.a</institution-id><institution-id institution-id-type="ISNI">0000 0000 9490 772X</institution-id><institution>Anhui Province Key Laboratory of Urological and Andrological Diseases Research and Medical Transformation, </institution><institution>Anhui Medical University, </institution></institution-wrap>Hefei, Anhui P.R. China </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03t1yn780</institution-id><institution-id institution-id-type="GRID">grid.412679.f</institution-id><institution-id institution-id-type="ISNI">0000 0004 1771 3402</institution-id><institution>Department of Clinical Laboratory, </institution><institution>The First Affiliated Hospital of Anhui Medical University, </institution></institution-wrap>Hefei, Anhui P.R. China </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00p1jee13</institution-id><institution-id institution-id-type="GRID">grid.440277.2</institution-id><institution>Department of Infectious Disease, </institution><institution>The Second People&#8217;s Hospital of Fuyang City, </institution></institution-wrap>Fuyang, Anhui P.R. China </aff></contrib-group><pub-date pub-type="epub"><day>26</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2025</year></pub-date><volume>16</volume><issue-id pub-id-type="pmc-issue-id">478248</issue-id><elocation-id>1738</elocation-id><history><date date-type="received"><day>19</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>21</day><month>7</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>26</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>28</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-28 14:25:15.427"><day>28</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="12672_2025_Article_3263.pdf"/><abstract id="Abs1"><p id="Par1">The increased expression of hsa-miR-21-5p in clear cell renal cell carcinoma (ccRCC) patients is closely linked to poor overall survival. Our predictive model, validated through tumor grading and staging, corresponds with enrichment analysis results and is further supported by PCR findings. Target gene predictions highlight the role of calcium ion transport and basement membrane functionality, with links to critical signaling pathways like JAK-STAT, cGMP-PKG, and sphingolipid, which play crucial roles in biological processes. Patients with higher levels of hsa-miR-21-5p show reduced responses to immunotherapy. In contrast, drug sensitivity analysis reveals increased vulnerability to drugs such as axitinib, sunitinib, and cabozantinib. This extensive investigation reveals the molecular complexities of ccRCC and suggests potential therapeutic options. In conclusion, upregulation of hsa-miR-21-5p in ccRCC is closely associated with tumor initiation and progression, indicating a poor prognosis. Its impact on the tumor microenvironment impairs the efficacy of immune therapies, contributing to adverse prognostic outcomes.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Clear renal cell carcinoma</kwd><kwd>hsa-miR-21-5p</kwd><kwd>Survival rate</kwd><kwd>Drug resistance</kwd><kwd>Immune evasion</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Science+Business Media LLC, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2">Renal cell carcinoma (RCC) comprises more than 90% of kidney malignancies [<xref ref-type="bibr" rid="CR1">1</xref>]. Urinary system malignancy is a commonly occurring neoplasm [<xref ref-type="bibr" rid="CR2">2</xref>&#8211;<xref ref-type="bibr" rid="CR4">4</xref>]. The occurrence of renal cell carcinoma has consistently increased in recent years, positioning it as one of the most rapidly expanding forms of cancer in North America [<xref ref-type="bibr" rid="CR5">5</xref>]. ccRCC is the predominant subtype, accounting for 80&#8211;90% of cases [<xref ref-type="bibr" rid="CR6">6</xref>]. According to survey data, more than 28% of patients are diagnosed with metastases at the time of initial diagnosis [<xref ref-type="bibr" rid="CR7">7</xref>]. Moreover, late-stage and metastatic ccRCC patients have notably low 5-year survival rates [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>], with limited responsiveness to standard chemotherapy and radiation therapy [<xref ref-type="bibr" rid="CR10">10</xref>]. Surgical intervention, immunosuppressive agents, and targeted medications are primary therapeutic modalities [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>], with surgery being preferred for localized and locally advanced stages [<xref ref-type="bibr" rid="CR13">13</xref>]. This can encompass either partial nephrectomy or radical nephrectomy [<xref ref-type="bibr" rid="CR14">14</xref>]. However, postsurgical recurrence and metastasis pose significant obstacles [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. Advanced RCC management primarily involves targeted treatments and immunosuppressive drugs [<xref ref-type="bibr" rid="CR17">17</xref>]. The current targeted therapies for advanced RCC can be classified into two primary categories. The initial category focuses on vascular endothelial growth factor (VEGF) and VEGF receptor (VEGFR), with a primary emphasis on antiangiogenic medicines. The second category pertains to the utilization of mTOR inhibitors, which are designed to specifically target the mTOR pathway. The initial category encompasses two primary classifications: tyrosine kinase inhibitors (TKIs), which represent a crucial collection of targeted therapeutic medications, and VEGF humanized monoclonal antibodies, exemplified by bevacizumab as a classic example [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. Targeted therapy focuses on the VEGF and mTOR pathways, whereas immunosuppressive drugs include PD-1 and CTLA-4 inhibitors [<xref ref-type="bibr" rid="CR20">20</xref>]. The second type comprises pharmaceutical substances such as ipilimumab [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. Targeted therapy has shown efficacy in extending progression-free survival [<xref ref-type="bibr" rid="CR1">1</xref>]; however, prolonged use may lead to drug resistance [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR23">23</xref>].</p><p id="Par3">MicroRNAs (miRNAs) are a group of short, single-stranded noncoding RNAs that exhibit a high degree of conservation in their nucleotide sequences. These sequences typically range from 20 to 22 base pairs in length [<xref ref-type="bibr" rid="CR24">24</xref>]. They function as precise regulators of gene expression [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>], playing crucial roles in tumorigenesis, progression, and drug resistance [<xref ref-type="bibr" rid="CR27">27</xref>&#8211;<xref ref-type="bibr" rid="CR30">30</xref>]. miRNAs interact with target mRNA 3&#8217;UTRs, suppress protein synthesis [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>], and play tissue-specific roles. Certain miRNAs indicate patient prognosis [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR33">33</xref>] and are correlated with ccRCC prognosis [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. Excessive hsa-miR-32 expression is correlated with adverse outcomes [<xref ref-type="bibr" rid="CR36">36</xref>], whereas miR-122 expression enhances ccRCC properties [<xref ref-type="bibr" rid="CR37">37</xref>]. Furthermore, considerable research has shed light on the role of hsa-miR-21-5p in the pathogenesis of diverse cancers. For example, this biomarker can be utilized for diagnostic purposes in patients with breast cancer [<xref ref-type="bibr" rid="CR38">38</xref>], plays a role in the onset of liver cancer [<xref ref-type="bibr" rid="CR39">39</xref>], and functions as a predictive factor for recurrence in young patients with gastric cancer [<xref ref-type="bibr" rid="CR40">40</xref>], among other various roles [<xref ref-type="bibr" rid="CR41">41</xref>]. A significant correlation is noted between clear cell renal cell cancer (ccRCC) and microRNAs (miRNAs). Notably, hsa-miR-21-5p plays a crucial role in regulating clear cell renal cell carcinoma (ccRCC) development and progression. Further research efforts are expected to expand our understanding of the molecular mechanisms behind ccRCC, hence providing new avenues for early detection, the identification of therapeutic targets, and the development of tailored therapeutic approaches for this disease.</p><p id="Par4">ccRCC is increasingly recognized as a metabolic disease, characterized by profound metabolic reprogramming including altered glycolysis, impaired mitochondrial oxidative phosphorylation (OxPhos), and dysregulated lipid metabolism [<xref ref-type="bibr" rid="CR42">42</xref>]. These alterations are critical for tumor growth, immune evasion, and therapy resistance. Notably, miR-21-5p has been implicated as a key regulator of cellular metabolism. It modulates mitochondrial respiration, fatty acid metabolism, and metabolic adaptation in several cancer types [<xref ref-type="bibr" rid="CR43">43</xref>]. However, its role in metabolic remodeling in ccRCC remains largely unexplored. Elucidating the metabolic functions of miR-21-5p in ccRCC may help uncover novel mechanisms of tumor progression and therapeutic vulnerability.</p></sec><sec id="Sec2"><title>Materials and methods</title><sec id="Sec3"><title>Compilation of transcriptomic, clinical, and MiRNA data</title><p id="Par5">The transcriptome data were obtained from the TCGA database, and the dataset was systematically organized by aligning sample names with their respective gene contents. The clinical information was acquired using a download process, wherein patient identifiers were cross-referenced with relevant clinical features such as survival time, survival status, age, sex, grade, and stage. Using the miRBase database, we successfully established a connection between mature miRNA names and sample identifiers, enabling us to obtain miRNA expression levels in each respective sample.</p></sec><sec id="Sec4"><title>Independent prognostic analysis and selection of ROC curves</title><p id="Par6">The clinical data were structured with a focus on key parameters (age, survival time, and status). R software (v4.2.2) was used to correlate the clinical data with the miRNA profiles (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05 for significance). If the threshold is met, the miRNA serves as an independent prognostic factor. We set a 5-year forecast timescale using tailored miRNA datasets. The ROC curve area filter was &#8805;&#8201;0.65. ROC indices for specific miRNAs were calculated in R.</p></sec><sec id="Sec5"><title>Extraction and differential analysis of pancancer data</title><p id="Par7">The focal gene chosen for our subsequent analysis was hsa-miR-21-5p. miRNA expression data for 33 unique tumour types were obtained from the TCGA database. Using Perl software, we conducted calculations to determine the expression levels of the target genes across a range of tumour types. In this study, we utilized the functionalities of R software to generate visual representations that successfully depict the pancancer expression data and their associated graphical insights.</p></sec><sec id="Sec6"><title>Survival and independent prognostic analyses with Kaplan&#8211;Meier and ROC curves</title><p id="Par8">P values were obtained by correlating the miRNA expression profiles with clinical variables (age, survival time, and survival status). R software was used to generate survival curves. Univariate analysis compared miRNA expression with clinical parameters for survival time and status, yielding p values. Multivariate analysis integrated all attributes to assess their correlation with survival, yielding p values. A forest plot was used to visualize the results. After establishing the miRNA&#8210;survival correlation, survival data were removed, and age, sex, grade, and TNM stage were retained. Missing values were marked as &#8220;unknown.&#8221; R was used to generate column line charts and calibration curves. pROC in R generated visualizations based on miRNA expression. A combined dataset produced a predicted ROC curve using R packages such as survival, sura miner, and timeROC for prognostic ROC visualizations.</p></sec><sec id="Sec7"><title>Differential expression analysis of miRNAs</title><p id="Par9">To validate the miRNAs identified using RNA sequencing, total RNA was extracted using the Animal Tissue Total RNA Extraction Kit (DP451) from Tiangen Biotech. Reverse transcription was performed with the PrimeScript&#8482; RT reagent Kit with gDNA Eraser (Takara), and cDNA amplification was conducted using TB Green<sup>&#174;</sup> Premix Ex Taq&#8482; II (Takara). All the qPCRs were run on an ABI 7500 PCR system (Applied Biosystems). Reactions were performed in 20&#160;&#181;l volumes using human &#946;-actin as the internal reference. The 2<sup>&#8722;&#916;&#916;Ct</sup> method was used for data analysis. Table&#160;<xref rid="Tab1" ref-type="table">1</xref> lists the qPCR primers used in this study. miRNA extraction was performed with the miRcute miRNA Extraction Kit (DP501), and cDNA synthesis was performed with the miRcute Enhanced miRNA cDNA Synthesis Kit (KR21100). Amplification was performed with the miRcute Enhanced miRNA Fluorescence Quantification Kit (FP411) on the ABI 7500 PCR system using the same calculation method used for mRNA.</p><p id="Par10">
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>This table lists the sequences of primers we used</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Gene</th><th align="left" colspan="1" rowspan="1">The sequence of primers</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">ZNF367</td><td align="left" colspan="1" rowspan="1">GGCTTCAGCGACTTCATGGT</td></tr><tr><td align="left" colspan="1" rowspan="1">FASLG</td><td align="left" colspan="1" rowspan="1">TGCCTTGGTAGGATTGGGC</td></tr><tr><td align="left" colspan="1" rowspan="1">ST3GAL6</td><td align="left" colspan="1" rowspan="1">ACTGCATTGCATATTATGGGGAA</td></tr><tr><td align="left" colspan="1" rowspan="1">YOD1</td><td align="left" colspan="1" rowspan="1">ATGTTTGGCCCCGCTAAAGG</td></tr><tr><td align="left" colspan="1" rowspan="1">KRIT1</td><td align="left" colspan="1" rowspan="1">GCCACCACCCTAGTCTCCTA</td></tr><tr><td align="left" colspan="1" rowspan="1">TIMP3</td><td align="left" colspan="1" rowspan="1">GAAGAGAGTACCGGCATCGG</td></tr><tr><td align="left" colspan="1" rowspan="1">IL-12&#160;A</td><td align="left" colspan="1" rowspan="1">GCACAGTGGAGGCCTGTTTA</td></tr><tr><td align="left" colspan="1" rowspan="1">GATAD2B</td><td align="left" colspan="1" rowspan="1">GAGCTAGCCGGGAGTTACAC</td></tr><tr><td align="left" colspan="1" rowspan="1">GTPBP10</td><td align="left" colspan="1" rowspan="1">ACAGCAAATTCCCAAATGCTGG</td></tr><tr><td align="left" colspan="1" rowspan="1">hsa-miR-21-5p</td><td align="left" colspan="1" rowspan="1">UAGCUUAUCAGACUGAUGUUGA</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec8"><title>Predicting miRNA target genes</title><p id="Par11">The homepage of the TargetScanHuman 8.0 database can be accessed via its official website, where users have the option to choose &#8220;human&#8221; as the designated species. To acquire a printable table containing the essential information, enter the specific miRNA name and click the submit button.</p></sec><sec id="Sec9"><title>Clinical statistics, coexpression analysis and coexpression heatmap</title><p id="Par12">Individual miRNA expression data and structured clinical input files are needed to conduct the analysis. R&#8217;s BiocManager and ggpubr packages were used to create informative box plots, and a chi-square test was performed (considered significant at a p value&#8201;&lt;&#8201;0.05). The files used included individual miRNA and mRNA expression files and target gene information. Correlation visualizations are generated using various R packages, such as BiocManager, ggpubr, tidyverse, ggplot2, and ggExtra. After coexpression analysis results were obtained, they were visualized by combining coexpression analysis files and creating heatmaps using BiocManager and the ComplexHeatmap package.</p></sec><sec id="Sec10"><title>GO, KEGG, and GSEA enrichment analyses</title><p id="Par13">The coexpression analysis results file required the installation of several essential packages, including BiocManager, ComplexHeatmap, DOSE, cluster profile, enrich plot, org.HS.eg.db, colorspace, stringi, ggplot2, circlize, and RColorBrewer. The significance level was set at <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05, and a corrected P value filter with a threshold of 0.05 was applied. We subsequently used R to create informative visual representations and systematically organize the data. Various packages, such as colorspace, stringi, DOSE, clusterProfiler, enrichplot, org.HS.eg.db, and ggplot2, were effectively used to manage the coexpression analysis results file, employing a P value threshold of 0.05 for both unadjusted and adjusted data.</p><p id="Par14">Additionally, we conducted a comprehensive study using sample files, individual miRNA expression data, and gene set files. We generated graphical representations skilfully with essential R packages such as BiocManager, DOSE, org.HS.eg.db, enrichplot, limma, and clusterProfiler while applying a filtering threshold of 1. These visual representations effectively highlighted the dataset&#8217;s most significantly enriched functions and pathways.</p></sec><sec id="Sec11"><title>Tumour microenvironment analysis and differential analysis</title><p id="Par15">In addition, we utilized sample files, individual microRNA expression data, and gene set files to conduct a comprehensive study. We skilfully generated graphical representations by employing essential R packages such as BiocManager, DOSE, org.HS.eg.db, enrichplot, limma, and clusterProfiler, while implementing a filtering threshold of 1. The visual representations successfully emphasized the dataset&#8217;s most notable enhanced functions and pathways.</p></sec><sec id="Sec12"><title>Immune cell infiltration, correlation, and immunotherapy analysis</title><p id="Par16">Transcriptome data, R pkgs BiocMgr, limma, and preprocessCore were used to analyse immune cell infiltration. The results were combined with miRNA data to generate scatter plots in R using BiocMgr, limma, ggpubr, vioplot, and ggExtra. Input files extracted from TIDE db (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://tide.dfci.harvard.edu/">http://tide.dfci.harvard.edu/</ext-link><italic toggle="yes">)</italic> were integrated with miRNA data and input files were submitted. Here, &#8220;Other&#8221; tumour type was selected, and the default settings were used. The table generated was downloaded. Violin plots were generated in R with BiocMgr, limma, and ggpubr pkgs. Note: Commands may vary on the basis of the R setup and pkg modifications.</p></sec><sec id="Sec13"><title>Drug sensitivity and differential analysis</title><p id="Par17">In this study, we used sample files, expression data from databases, and drug sensitivity scoring files. To conduct our analyses, we employed packages such as BiocManager, limma, OncoPredict, and other relevant tools. The next phase involves evaluating drug sensitivity for multiple drugs using available resources. We carefully assessed drug responsiveness using single miRNA expression inputs and drug sensitivity rating files. An iterative approach allowed us to identify medications with significant sensitivity. After installing necessary packages such as BiocManager, limma, ggplot2, and ggpubr and applying a filtering threshold of pFilter&#8201;=&#8201;0.05, we used R to create box plots. The iterative methodology involved cycling through the numerous medications mentioned in the accompanying documents. Importantly, specific approaches and package instructions can be tailored to match the unique characteristics of the study and dataset at hand.</p></sec></sec><sec id="Sec14"><title>Results</title><sec id="Sec15"><title>Differential miRNA selection</title><p id="Par18">A filtering method based on the criteria of |logFC| &gt;1 and an adjusted p value (FDR)&#8201;&lt;&#8201;0.05 was used in this study. This strategy increased the accuracy of selecting miRNAs that exhibited differential expression. Next, we focused on visualizing the top 100 upregulated and downregulated miRNAs (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). Figure&#160;<xref rid="Fig1" ref-type="fig">1</xref> shows the colour scheme used to represent the expression levels in the normal and tumour group samples. Specifically, samples from the normal group are displayed in blue, indicating low expression, whereas samples from the tumour group are highlighted in red, indicating high expression. The miRNAs targeted are indicated on the right side of the graph. The utilization of this graphical depiction facilitated the prompt identification of highly expressed miRNAs within the tumour cohort, including noteworthy examples such as hsa-miR-21-3p, hsa-miR-625-3p, and hsa-miR-21-5p, among others. Given that miR-21-5p has also been implicated in regulating mitochondrial function and lipid metabolism in cancer, its overexpression in ccRCC may contribute not only to proliferation but also to metabolic adaptation.</p><p id="Par19">
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Heatmap of 100 differentially expressed miRNAs. The figure displays the top 100 significantly upregulated and downregulated miRNAs. Red represents high expression, while blue represents low expression</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e540" position="float" orientation="portrait" xlink:href="12672_2025_3263_Fig1_HTML.jpg"/></fig>
</p></sec><sec id="Sec16"><title>Differential gene analysis and validation</title><p id="Par20">A rigorous methodology was employed for the selection of the target gene, integrating the area under the receiver operating characteristic (ROC) curve and findings from an independent prognostic study, which included Kaplan&#8211;Meier (K&#8211;M) survival curves and the Cox proportional hazards model. Consequently, hsa-miR-21-5p emerged as the primary candidate for further investigation. As shown in Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>A, a significant differential expression of hsa-miR-21-5p in ccRCC was observed (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05), indicating its overexpression in tumor tissues. Analysis of individual tumor samples revealed significant variability in hsa-miR-21-5p expression across ccRCC cases (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05, Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>B). In the paired differential analysis, we identified distinct discrepancies between normal and malignant samples. Figure&#160;<xref rid="Fig2" ref-type="fig">2</xref>C presents data points representing unique groups, with connecting lines indicating paired tumor and adjacent normal samples from the same patient. Notably, the connecting lines exhibit an upward trend, suggesting a higher abundance of hsa-miR-21-5p in tumor tissues. A survival analysis was conducted, and the survival curves, shown in Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>E, demonstrated a progressive decline in survival rates over time. Upon classifying samples into two groups based on hsa-miR-21-5p expression levels, statistically significant differences in survival rates were observed (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05), with the low expression group displaying a more favorable prognosis compared to the high expression group. Furthermore, an independent prognostic study confirmed that hsa-miR-21-5p can independently serve as a prognostic marker, unaffected by other clinical variables (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>F, G). Additionally, qPCR analysis comparing hsa-miR-21-5p levels in tumor and adjacent nontumor tissues revealed a significantly higher abundance of hsa-miR-21-5p in tumor tissues (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05, Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>D).</p><p id="Par21">
<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Screening of differential miRNAs. <bold>A</bold> Calibration curve for predicting patient survival to assess the accuracy of the prediction. <bold>B</bold> Predicting patient survival based on patient characteristics. <bold>C</bold> The area under the curve represents the accuracy of the prediction. <bold>D</bold> Assessing the accuracy of predicting survival time. <bold>E</bold>&#8211;<bold>G</bold> Assessment of differences between various characteristics, &#8727;<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05, &#8727;&#8727;<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01, &#8727;&#8727;&#8727;<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e614" position="float" orientation="portrait" xlink:href="12672_2025_3263_Fig2_HTML.jpg"/></fig>
</p></sec><sec id="Sec17"><title>Column line plot and calibration curve</title><p id="Par22">The results indicated that the C-index value for the target miRNA surpassed 0.75, indicating a high accuracy level in predicting patient survival (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>A). This finding is demonstrated in the column line plot. A higher scale reflects individual scores (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>B). Using this scoring method, it is possible to calculate scores for every clinical trait. The scores can be aggregated to obtain a thorough score for an individual sample, allowing for the prediction of patient survival duration.</p></sec><sec id="Sec18"><title>Diagnosis ROC curve and prognosis ROC curve</title><p id="Par23">The primary emphasis of our analysis of the ROC curve involves evaluating the area under the curve (AUC). A higher AUC indicates increased accuracy in differentiating between normal and malignant samples using hsa-miR-21-5p. As depicted in Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>C, the area under the curve (AUC) exceeded 0.9, indicating a significant level of accuracy attained by the utilization of hsa-miR-21-5p in distinguishing between normal and malignant samples. Furthermore, the AUC values for the time intervals of one year, three years, and five years all surpassed the threshold of 0.65 (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>D). These findings support the reliable predictive accuracy of hsa-miR-21-5p throughout these specific periods.</p></sec><sec id="Sec19"><title>Statistical analysis of clinical data</title><p id="Par24">The statistical analysis revealed significant differences (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05) in sex, M stage, and N stage between the high- and low-expression groups of hsa-miR-21-5p, as shown in Table&#160;<xref rid="Tab2" ref-type="table">2</xref>. Figure&#160;<xref rid="Fig3" ref-type="fig">3</xref>E&#8211;K displays the clinical characteristics, specifically tumour stage, on the X-axis. Using Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>K as an illustrative example, the diagram is categorized into four distinct stages, namely, stages 1, 2, 3, and 4. In the context of this study, the y-axis is utilized to depict the relative expression levels of miRNAs. An analysis of these visual representations revealed statistically significant differences in hsa-miR-21-5p expression among the different clinical groups (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05). As shown in Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>K, hsa-miR-21-5p expression levels varied across several stages, namely, stage 1 and stage 3, stage 1 and stage 4, stage 2 and stage 3, as well as stage 2 and stage 4.</p><p id="Par25">
<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Evaluation and validation of the predictive power of the column charts. <bold>A</bold> Calibration curve for predicting patient survival to assess the accuracy of the prediction. <bold>B</bold> Predicting patient survival based on patient characteristics. <bold>C</bold> The area under the curve represents the accuracy of the prediction. <bold>D</bold> Assessing the accuracy of predicting survival time. <bold>E</bold>&#8211;<bold>K</bold> Assessment of differences between various characteristics, &#8727;<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05, &#8727;&#8727;<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01, &#8727;&#8727;&#8727;<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e696" position="float" orientation="portrait" xlink:href="12672_2025_3263_Fig3_HTML.jpg"/></fig>
</p><p id="Par26">
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>The statistical analysis revealed significant differences (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05) in gender, M stage, and N stage between the high and low expression groups of hsa-miR-21-5p</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Covariates</th><th align="left" colspan="1" rowspan="1">Group</th><th align="left" colspan="1" rowspan="1">Total</th><th align="left" colspan="1" rowspan="1">Low</th><th align="left" colspan="1" rowspan="1">High</th><th align="left" colspan="1" rowspan="1">Chi</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Age</td><td align="left" colspan="1" rowspan="1">&lt;=65</td><td char="." align="char" colspan="1" rowspan="1">342 (66.28%)</td><td char="." align="char" colspan="1" rowspan="1">177 (68.6%)</td><td char="." align="char" colspan="1" rowspan="1">165 (63.95%)</td><td align="left" rowspan="2" colspan="1">1.0492</td><td align="left" rowspan="2" colspan="1">0.3057</td></tr><tr><td align="left" colspan="1" rowspan="1">Age</td><td align="left" colspan="1" rowspan="1">&gt;&#8201;65</td><td char="." align="char" colspan="1" rowspan="1">174 (33.72%)</td><td char="." align="char" colspan="1" rowspan="1">81 (31.4%)</td><td char="." align="char" colspan="1" rowspan="1">93 (36.05%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Gender</td><td align="left" colspan="1" rowspan="1">FEMALE</td><td char="." align="char" colspan="1" rowspan="1">181 (35.08%)</td><td char="." align="char" colspan="1" rowspan="1">106 (41.09%)</td><td char="." align="char" colspan="1" rowspan="1">75 (29.07%)</td><td align="left" rowspan="2" colspan="1">7.6589</td><td align="left" rowspan="2" colspan="1">0.0056</td></tr><tr><td align="left" colspan="1" rowspan="1">Gender</td><td align="left" colspan="1" rowspan="1">MALE</td><td char="." align="char" colspan="1" rowspan="1">335 (64.92%)</td><td char="." align="char" colspan="1" rowspan="1">152 (58.91%)</td><td char="." align="char" colspan="1" rowspan="1">183 (70.93%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Grade</td><td align="left" colspan="1" rowspan="1">G1</td><td char="." align="char" colspan="1" rowspan="1">13 (2.56%)</td><td char="." align="char" colspan="1" rowspan="1">11 (4.38%)</td><td char="." align="char" colspan="1" rowspan="1">2 (0.78%)</td><td align="left" rowspan="4" colspan="1">45.339</td><td align="left" rowspan="4" colspan="1">0</td></tr><tr><td align="left" colspan="1" rowspan="1">Grade</td><td align="left" colspan="1" rowspan="1">G2</td><td char="." align="char" colspan="1" rowspan="1">218 (42.91%)</td><td char="." align="char" colspan="1" rowspan="1">133 (52.99%)</td><td char="." align="char" colspan="1" rowspan="1">85 (33.07%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Grade</td><td align="left" colspan="1" rowspan="1">G3</td><td char="." align="char" colspan="1" rowspan="1">202 (39.76%)</td><td char="." align="char" colspan="1" rowspan="1">92 (36.65%)</td><td char="." align="char" colspan="1" rowspan="1">110 (42.8%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Grade</td><td align="left" colspan="1" rowspan="1">G4</td><td char="." align="char" colspan="1" rowspan="1">75 (14.76%)</td><td char="." align="char" colspan="1" rowspan="1">15 (5.98%)</td><td char="." align="char" colspan="1" rowspan="1">60 (23.35%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Stage</td><td align="left" colspan="1" rowspan="1">Stage I</td><td char="." align="char" colspan="1" rowspan="1">25 3(49.32%)</td><td char="." align="char" colspan="1" rowspan="1">154 (59.69%)</td><td char="." align="char" colspan="1" rowspan="1">99 (38.82%)</td><td align="left" rowspan="4" colspan="1">28.4514</td><td align="left" rowspan="4" colspan="1">0</td></tr><tr><td align="left" colspan="1" rowspan="1">Stage</td><td align="left" colspan="1" rowspan="1">Stage II</td><td char="." align="char" colspan="1" rowspan="1">55 (10.72%)</td><td char="." align="char" colspan="1" rowspan="1">30 (11.63%)</td><td char="." align="char" colspan="1" rowspan="1">25 (9.8%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Stage</td><td align="left" colspan="1" rowspan="1">Stage III</td><td char="." align="char" colspan="1" rowspan="1">123 (23.98%)</td><td char="." align="char" colspan="1" rowspan="1">46 (17.83%)</td><td char="." align="char" colspan="1" rowspan="1">77 (30.2%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Stage</td><td align="left" colspan="1" rowspan="1">Stage IV</td><td char="." align="char" colspan="1" rowspan="1">82 (15.98%)</td><td char="." align="char" colspan="1" rowspan="1">28 (10.85%)</td><td char="." align="char" colspan="1" rowspan="1">54 (21.18%)</td></tr><tr><td align="left" colspan="1" rowspan="1">T</td><td align="left" colspan="1" rowspan="1">T1</td><td char="." align="char" colspan="1" rowspan="1">259 (50.19%)</td><td char="." align="char" colspan="1" rowspan="1">154 (59.69%)</td><td char="." align="char" colspan="1" rowspan="1">105 (40.7%)</td><td align="left" rowspan="4" colspan="1">25.172</td><td align="left" rowspan="4" colspan="1">0</td></tr><tr><td align="left" colspan="1" rowspan="1">T</td><td align="left" colspan="1" rowspan="1">T2</td><td char="." align="char" colspan="1" rowspan="1">67 (12.98%)</td><td char="." align="char" colspan="1" rowspan="1">35 (13.57%)</td><td char="." align="char" colspan="1" rowspan="1">32 (12.4%)</td></tr><tr><td align="left" colspan="1" rowspan="1">T</td><td align="left" colspan="1" rowspan="1">T3</td><td char="." align="char" colspan="1" rowspan="1">179 (34.69%)</td><td char="." align="char" colspan="1" rowspan="1">67 (25.97%)</td><td char="." align="char" colspan="1" rowspan="1">112 (43.41%)</td></tr><tr><td align="left" colspan="1" rowspan="1">T</td><td align="left" colspan="1" rowspan="1">T4</td><td char="." align="char" colspan="1" rowspan="1">11 (2.13%)</td><td char="." align="char" colspan="1" rowspan="1">2 (0.78%)</td><td char="." align="char" colspan="1" rowspan="1">9 (3.49%)</td></tr><tr><td align="left" colspan="1" rowspan="1">M</td><td align="left" colspan="1" rowspan="1">M0</td><td char="." align="char" colspan="1" rowspan="1">406 (83.88%)</td><td char="." align="char" colspan="1" rowspan="1">218 (88.98%)</td><td char="." align="char" colspan="1" rowspan="1">188 (78.66%)</td><td align="left" rowspan="2" colspan="1">8.7804</td><td align="left" rowspan="2" colspan="1">0.003</td></tr><tr><td align="left" colspan="1" rowspan="1">M</td><td align="left" colspan="1" rowspan="1">M1</td><td char="." align="char" colspan="1" rowspan="1">78 (16.12%)</td><td char="." align="char" colspan="1" rowspan="1">27 (11.02%)</td><td char="." align="char" colspan="1" rowspan="1">51 (21.34%)</td></tr><tr><td align="left" colspan="1" rowspan="1">N</td><td align="left" colspan="1" rowspan="1">N0</td><td char="." align="char" colspan="1" rowspan="1">228 (93.06%)</td><td char="." align="char" colspan="1" rowspan="1">112 (99.12%)</td><td char="." align="char" colspan="1" rowspan="1">116 (87.88%)</td><td align="left" rowspan="2" colspan="1">10.2271</td><td align="left" rowspan="2" colspan="1">0.0014</td></tr><tr><td align="left" colspan="1" rowspan="1">N</td><td align="left" colspan="1" rowspan="1">N1</td><td char="." align="char" colspan="1" rowspan="1">17 (6.94%)</td><td char="." align="char" colspan="1" rowspan="1">1 (0.88%)</td><td char="." align="char" colspan="1" rowspan="1">16 (12.12%)</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec20"><title>Predicting miRNA target genes</title><p id="Par27">Table&#160;<xref rid="Tab3" ref-type="table">3</xref> displays the data concerning the predicted target genes of hsa-miR-21-5p. A decreased aggregate score indicates an increased probability of a gene being targeted by a miRNA. Based on the obtained score, it can be inferred that YOD1 is a gene that is more likely to be targeted by hsa-miR-21-5p.</p><p id="Par28">
<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>The presented information represents the predicted target genes of hsa-miR-21-5p</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">miRNA</th><th align="left" colspan="1" rowspan="1">Gene</th><th align="left" colspan="1" rowspan="1">Cor</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">hsa-miR-21-5p</td><td align="left" colspan="1" rowspan="1">TIMP3</td><td char="." align="char" colspan="1" rowspan="1">&#8211; 0.43184</td><td align="left" colspan="1" rowspan="1">1.31E&#8211; 35</td></tr><tr><td align="left" colspan="1" rowspan="1">hsa-miR-21-5p</td><td align="left" colspan="1" rowspan="1">ARHGAP24</td><td char="." align="char" colspan="1" rowspan="1">&#8211; 0.33667</td><td align="left" colspan="1" rowspan="1">4.84E&#8211; 26</td></tr><tr><td align="left" colspan="1" rowspan="1">hsa-miR-21-5p</td><td align="left" colspan="1" rowspan="1">DUSP8</td><td char="." align="char" colspan="1" rowspan="1">&#8211; 0.36093</td><td align="left" colspan="1" rowspan="1">1.79E&#8211; 25</td></tr><tr><td align="left" colspan="1" rowspan="1">hsa-miR-21-5p</td><td align="left" colspan="1" rowspan="1">CPEB3</td><td char="." align="char" colspan="1" rowspan="1">&#8211; 0.40535</td><td align="left" colspan="1" rowspan="1">5.44E&#8211; 25</td></tr><tr><td align="left" colspan="1" rowspan="1">hsa-miR-21-5p</td><td align="left" colspan="1" rowspan="1">THRB</td><td char="." align="char" colspan="1" rowspan="1">&#8211; 0.50936</td><td align="left" colspan="1" rowspan="1">3.79E&#8211; 24</td></tr><tr><td align="left" colspan="1" rowspan="1">hsa-miR-21-5p</td><td align="left" colspan="1" rowspan="1">SESTD1</td><td char="." align="char" colspan="1" rowspan="1">&#8211; 0.32979</td><td align="left" colspan="1" rowspan="1">3.07E&#8211; 23</td></tr><tr><td align="left" colspan="1" rowspan="1">hsa-miR-21-5p</td><td align="left" colspan="1" rowspan="1">AP1AR</td><td char="." align="char" colspan="1" rowspan="1">&#8211; 0.30316</td><td align="left" colspan="1" rowspan="1">6.06E&#8211; 22</td></tr><tr><td align="left" colspan="1" rowspan="1">hsa-miR-21-5p</td><td align="left" colspan="1" rowspan="1">ZNF704</td><td char="." align="char" colspan="1" rowspan="1">&#8211; 0.30109</td><td align="left" colspan="1" rowspan="1">2.32E&#8211; 21</td></tr><tr><td align="left" colspan="1" rowspan="1">hsa-miR-21-5p</td><td align="left" colspan="1" rowspan="1">NIPAL1</td><td char="." align="char" colspan="1" rowspan="1">&#8211; 0.30394</td><td align="left" colspan="1" rowspan="1">2.61E&#8211; 20</td></tr><tr><td align="left" colspan="1" rowspan="1">hsa-miR-21-5p</td><td align="left" colspan="1" rowspan="1">LIFR</td><td char="." align="char" colspan="1" rowspan="1">&#8211; 0.44046</td><td align="left" colspan="1" rowspan="1">1.70E&#8211; 19</td></tr><tr><td align="left" colspan="1" rowspan="1">hsa-miR-21-5p</td><td align="left" colspan="1" rowspan="1">ABHD10</td><td char="." align="char" colspan="1" rowspan="1">&#8211; 0.43583</td><td align="left" colspan="1" rowspan="1">1.97E&#8211; 19</td></tr><tr><td align="left" colspan="1" rowspan="1">hsa-miR-21-5p</td><td align="left" colspan="1" rowspan="1">RAVER2</td><td char="." align="char" colspan="1" rowspan="1">&#8211; 0.33026</td><td align="left" colspan="1" rowspan="1">2.06E&#8211; 17</td></tr><tr><td align="left" colspan="1" rowspan="1">hsa-miR-21-5p</td><td align="left" colspan="1" rowspan="1">ANKRD46</td><td char="." align="char" colspan="1" rowspan="1">&#8211; 0.41689</td><td align="left" colspan="1" rowspan="1">4.36E&#8211; 17</td></tr><tr><td align="left" colspan="1" rowspan="1">hsa-miR-21-5p</td><td align="left" colspan="1" rowspan="1">SOWAHC</td><td char="." align="char" colspan="1" rowspan="1">&#8211; 0.32367</td><td align="left" colspan="1" rowspan="1">6.14E&#8211; 17</td></tr></tbody></table><table-wrap-foot><p>A lower combined score suggests a higher likelihood of a gene being a target of the miRNA</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec21"><title>Coexpression analysis</title><p id="Par29">Our study aimed to examine the inhibitory connections between hsa-miR-21-5p and its target genes. A negative regulatory relationship is deduced when the correlation coefficient is less than zero and the p value of the correlation is less than 0.05. A correlation plot was generated for each gene that exhibited a significant association (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>). The plots consistently revealed a decreasing trend in gene expression, indicating a negative regulatory relationship between the target gene and hsa-miR-21-5p. The coexpression analysis results can be effectively represented in a coexpression heatmap (Table&#160;<xref rid="Tab4" ref-type="table">4</xref>; Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>). Genes annotated with asterisks are significantly associated with hsa-miR-21-5p. The arrangement of the samples in Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref> is based on increasing hsa-miR-21-5p expression from the left to the right. Notably, samples are classified into high- and low- hsa-miR-21-5p expression groups based on the median expression value. When hsa-miR-21-5p expression increases, there is a tendency for gene expression to decrease. This observed pattern demonstrates the negative regulatory interaction between these genes and hsa-miR-21-5p.</p><p id="Par30">
<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>Expression of genes with significant correlation. The regulatory relationship between target genes and has-miR-21-5p</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1174" position="float" orientation="portrait" xlink:href="12672_2025_3263_Fig4_HTML.jpg"/></fig>
</p><p id="Par31">
<fig id="Fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><p>Heatmap of co-expressed genes with significant correlation. Genes significantly associated with hsa-miR-21-5p exhibit a decrease in expression as hsa-miR-21-5p expression rises, indicating a negative regulatory relationship between these genes and hsa-miR-21-5p</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1184" position="float" orientation="portrait" xlink:href="12672_2025_3263_Fig5_HTML.jpg"/></fig>
</p><p id="Par32">
<table-wrap id="Tab4" position="float" orientation="portrait"><label>Table 4</label><caption><p>A negative regulatory relationship is inferred if the correlation coefficient is &lt;&#8201;0 and the correlation&#8217;s p-value is &lt;&#8201;0.05</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Representative miRNA</th><th align="left" colspan="1" rowspan="1">Target gene</th><th align="left" colspan="1" rowspan="1">Representative transcript</th><th align="left" colspan="1" rowspan="1">Cumulative weighted context&#8201;+&#8201;+&#8201;score</th><th align="left" colspan="1" rowspan="1">Total context&#8201;+&#8201;+&#8201;score</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">hsa-miR-21-5p</td><td align="left" colspan="1" rowspan="1">YOD1</td><td align="left" colspan="1" rowspan="1">ENST00000315927.4</td><td char="." align="char" colspan="1" rowspan="1">&#8211; 0.5</td><td char="." align="char" colspan="1" rowspan="1">&#8211; 0.75</td></tr><tr><td align="left" colspan="1" rowspan="1">hsa-miR-21-5p</td><td align="left" colspan="1" rowspan="1">ST3GAL6</td><td align="left" colspan="1" rowspan="1">ENST00000265261.6</td><td char="." align="char" colspan="1" rowspan="1">&#8211; 0.37</td><td char="." align="char" colspan="1" rowspan="1">&#8211; 0.74</td></tr><tr><td align="left" colspan="1" rowspan="1">hsa-miR-21-5p</td><td align="left" colspan="1" rowspan="1">ZNF367</td><td align="left" colspan="1" rowspan="1">ENST00000375256.4</td><td char="." align="char" colspan="1" rowspan="1">&#8211; 0.72</td><td char="." align="char" colspan="1" rowspan="1">&#8211; 0.72</td></tr><tr><td align="left" colspan="1" rowspan="1">hsa-miR-21-5p</td><td align="left" colspan="1" rowspan="1">GTPBP10</td><td align="left" colspan="1" rowspan="1">ENST00000222511.6</td><td char="." align="char" colspan="1" rowspan="1">&#8211; 0.02</td><td char="." align="char" colspan="1" rowspan="1">&#8211; 0.72</td></tr><tr><td align="left" colspan="1" rowspan="1">hsa-miR-21-5p</td><td align="left" colspan="1" rowspan="1">KRIT1</td><td align="left" colspan="1" rowspan="1">ENST00000394507.1</td><td char="." align="char" colspan="1" rowspan="1">&#8211; 0.66</td><td char="." align="char" colspan="1" rowspan="1">&#8211; 0.69</td></tr><tr><td align="left" colspan="1" rowspan="1">hsa-miR-21-5p</td><td align="left" colspan="1" rowspan="1">TIMP3</td><td align="left" colspan="1" rowspan="1">ENST00000266085.6</td><td char="." align="char" colspan="1" rowspan="1">&#8211; 0.46</td><td char="." align="char" colspan="1" rowspan="1">&#8211; 0.68</td></tr><tr><td align="left" colspan="1" rowspan="1">hsa-miR-21-5p</td><td align="left" colspan="1" rowspan="1">IL12A</td><td align="left" colspan="1" rowspan="1">ENST00000466512.1</td><td char="." align="char" colspan="1" rowspan="1">&#8211; 0.65</td><td char="." align="char" colspan="1" rowspan="1">&#8211; 0.65</td></tr><tr><td align="left" colspan="1" rowspan="1">hsa-miR-21-5p</td><td align="left" colspan="1" rowspan="1">GATAD2B</td><td align="left" colspan="1" rowspan="1">ENST00000368655.4</td><td char="." align="char" colspan="1" rowspan="1">&#8211; 0.21</td><td char="." align="char" colspan="1" rowspan="1">&#8211; 0.65</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec22"><title>GO enrichment analysis</title><p id="Par33">By conducting GO enrichment analysis, valuable insights can be obtained regarding the pathways and activities that are enriched with coexpressed genes. In Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>A, the outermost circle depicts Gene Ontology (GO) identifiers (IDs). The GO results were categorized into three distinct categories: biological process (BP), cellular component (CC), and molecular function (MF). These categories are visually distinguished through colour coding, with BP represented by blue, CC represented by green, and MF represented by purple. The second circle represents the number of genes associated with each GO term. The third circle visually represents the number of coexpressed genes enriched in each GO term. The fourth circle presents the relative distribution of genes. Figure&#160;<xref rid="Fig6" ref-type="fig">6</xref>B shows a bubble plot representing the proportion of genes enriched in each GO term on the horizontal axis, with the titles of the GO terms displayed on the vertical axis. The size of the bubble is proportional to the number of genes that are enriched in a certain GO term, whereas the colour of the bubble indicates the enrichment significance level. Specifically, a redder bubble indicates a greater level of significance in the enrichment of coexpressed genes. Plot analysis revealed notable enrichment of calcium ion transport in the BP category. Additionally, the basal membrane was strongly associated with the CC category. In terms of MF, the dominant features included mRNA regulatory element binding, translation inhibitory factor activity, and channel inhibitor activity. The bar plot illustrates the relationship between the number of genes enriched in each GO term and the corresponding GO term names, with the horizontal axis representing the former and the vertical axis representing the latter (Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>C). The bar colour indicates the enrichment significance level, with a darker shade representing a greater degree of importance in the coexpression of genes. The presented visualization provides more evidence that the transport of calcium ions is particularly noteworthy in the biological process of blood pressure regulation. Additionally, these findings highlight the importance of the basal membrane in cellular communication. Furthermore, visualization emphasized the molecular functions of mRNA regulatory element binding, translation inhibitory factor activity, and channel inhibitor activity.</p></sec><sec id="Sec23"><title>KEGG enrichment analysis</title><p id="Par34">Insights into the enrichment of coexpressed genes within specific pathways were obtained through KEGG enrichment analysis. The present research employs bar and bubble charts as visual aids to represent the enrichments. In Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>D, the y-axis indicates the names of the pathways, whereas the x-axis displays the count of enriched genes in each respective route. The colouration of the bars serves as an indicator of the relative degree of the enrichment, where a more intense hue of red corresponds to a heightened level of significance. The graph shows that the coexpressed genes are significantly enriched in pathways such as the cancer-related microRNA, phospholipid, JAK-STAT, and cGMP-PKG signalling pathways. The vertical axis represents the names of the pathways, whereas the horizontal axis represents the ratios of genes (Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>E). The diameters of the circles are indicative of the number of genes that are enriched within each pathway. Moreover, the intensity of their colour represents the level of statistical significance associated with the enrichment. A more intense crimson hue signifies a greater degree of significance. The graph shows significant enrichment of coexpressed genes in many pathways, including the JAK-STAT signalling pathway, cancer-related microRNA pathway, phospholipid signalling pathway, and cGMP-PKG signalling pathway.</p><p id="Par35">
<fig id="Fig6" position="float" orientation="portrait"><label>Fig. 6</label><caption><p>Functional enrichment analysis reveals distinct biological pathways between high- and low-risk groups. <bold>A</bold> The representation of enriched genes can be described in terms of categories, numbers, and proportions. <bold>B</bold>, <bold>C</bold> The GO enrichment analysis results indicate significant enrichment in calcium ion transport and basal membrane. <bold>D</bold>, <bold>E</bold> The KEGG analysis results of enriched pathways for co-expressed genes are as follows</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1348" position="float" orientation="portrait" xlink:href="12672_2025_3263_Fig6_HTML.jpg"/></fig>
</p></sec><sec id="Sec24"><title>Gene set enrichment analysis</title><p id="Par36">Gene set enrichment analysis (GSEA) can be employed to examine the functional or pathway enrichment observed in the hsa-miR-21-5p high and low expression cohorts. In this graphical representation, the X-axis depicts the genes arranged in a sorted manner, whereas the y-axis represents the enrichment values. The diverse chromatic curves correspond to distinct functions or pathways. As illustrated in Fig.&#160;<xref rid="Fig7" ref-type="fig">7</xref>A, the peaks of the curves are located in the lower right quadrant, suggesting the activation of many pathways, including fatty acid metabolism, glycolysis gluconeogenesis, oxidative phosphorylation, PPAR signalling, and retinol metabolism, in the low hsa-miR-21-5p expression group. In contrast, the data presented in Fig.&#160;<xref rid="Fig7" ref-type="fig">7</xref>B reveal the presence of peaks in the left and upper regions. This observation indicates the potential activation of various functions and pathways associated with phagosome recognition, immune complex activities, antigen binding, immune globulin receptor binding, immune complex circulation, and retinol metabolism in the high hsa-miR-21-5p expression group. Several of the predicted miR-21-5p target genes were involved in metabolic pathways, such as fatty acid metabolism, oxidative phosphorylation, and lipid biosynthesis, indicating that miR-21-5p may exert oncogenic functions through metabolic regulation.</p><p id="Par37">
<fig id="Fig7" position="float" orientation="portrait"><label>Fig. 7</label><caption><p>Enrichment analysis reveals different biological pathways between the high and low expression groups of hsa-miR-21-5p. <bold>A</bold>The low-expression group is primarily enriched in pathways related to fatty acid metabolism, glycolysis/gluconeogenesis, oxidative phosphorylation, PPAR signaling pathway, and retinol metabolism. <bold>B</bold> The high-expression group is primarily enriched in functions related to phagocytic recognition, immunoglobulin complex function, immunoglobulin complex circulation function, antigen binding, immunoglobulin receptor binding, and retinol metabolism pathway</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1375" position="float" orientation="portrait" xlink:href="12672_2025_3263_Fig7_HTML.jpg"/></fig>
</p></sec><sec id="Sec25"><title>Tumour microenvironment analysis and differential analysis</title><p id="Par38">As part of the tumour microenvironment analysis, we computed a score to quantify the milieu characteristics for each sample. In Table&#160;<xref rid="Tab5" ref-type="table">5</xref>, the composite score is calculated by summing the scores obtained in the second and third columns. A greater score attributed to stromal cells indicates an increased abundance of these cells in the examined specimen. Similarly, an elevated score for immune cells signifies a greater prevalence of immune cells in the sample. The comprehensive score is a measure that encompasses the combined impact of the stromal and immune cells present in a sample. Higher comprehensive scores are indicative of a reduced level of tumour purity in the sample. By examining distinct tumour microenvironments, it is possible to explore potential difference in tumour microenvironment scores between groups with high and low hsa-miR-21-5p expression. We were able to assess significant differences between the groups as mentioned above and determine the corresponding p values (Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>D). P values less than 0.001 are denoted by three asterisks, whereas p values less than 0.01 are represented by a single asterisk. Here, different asterisks indicate p values less than 0.05. The graph illustrates the statistical significance of the differences in stromal cells, immune cells, and the total composite score between the high and low hsa-miR-21-5p expression groups. These differences are indicated by the presence of three stars above each respective score. Furthermore, the scores within the high-expression group regularly outperformed those within the low-expression group, indicating a greater abundance of stromal cells and immune cells and a concurrent presence of both cell types in the high-expression group.</p><p id="Par39">
<table-wrap id="Tab5" position="float" orientation="portrait"><label>Table 5</label><caption><p>The estimatescore reflects the combined content of both stromal and immune cells in the sample</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">ID</th><th align="left" colspan="1" rowspan="1">StromalScore</th><th align="left" colspan="1" rowspan="1">ImmuneScore</th><th align="left" colspan="1" rowspan="1">ESTIMATEScore</th><th align="left" colspan="1" rowspan="1">TumorPurity</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">TCGA-CJ-4639-01A-02R-1325-07</td><td align="left" colspan="1" rowspan="1">752.0523652</td><td align="left" colspan="1" rowspan="1">1892.302156</td><td align="left" colspan="1" rowspan="1">2.64E&#8201;+&#8201;03</td><td char="." align="char" colspan="1" rowspan="1">0.54605553</td></tr><tr><td align="left" colspan="1" rowspan="1">TCGA-BP-4964-01A-01R-1334-07</td><td align="left" colspan="1" rowspan="1">813.3042762</td><td align="left" colspan="1" rowspan="1">1619.136459</td><td align="left" colspan="1" rowspan="1">2.43E&#8201;+&#8201;03</td><td char="." align="char" colspan="1" rowspan="1">0.57184659</td></tr><tr><td align="left" colspan="1" rowspan="1">TCGA-A3-A8OW-01A-11R-A37O-07</td><td align="left" colspan="1" rowspan="1">613.1166871</td><td align="left" colspan="1" rowspan="1">1308.549439</td><td align="left" colspan="1" rowspan="1">1.92E&#8201;+&#8201;03</td><td char="." align="char" colspan="1" rowspan="1">0.63168963</td></tr><tr><td align="left" colspan="1" rowspan="1">TCGA-BP-4983-01A-01R-1334-07</td><td align="left" colspan="1" rowspan="1">764.345521</td><td align="left" colspan="1" rowspan="1">2715.189537</td><td align="left" colspan="1" rowspan="1">3.48E&#8201;+&#8201;03</td><td char="." align="char" colspan="1" rowspan="1">0.43951059</td></tr><tr><td align="left" colspan="1" rowspan="1">TCGA-B0-5698-01A-11R-1672-07</td><td align="left" colspan="1" rowspan="1">615.9809388</td><td align="left" colspan="1" rowspan="1">2143.575542</td><td align="left" colspan="1" rowspan="1">2.76E&#8201;+&#8201;03</td><td char="." align="char" colspan="1" rowspan="1">0.53181153</td></tr><tr><td align="left" colspan="1" rowspan="1">TCGA-BP-5186-01A-01R-1426-07</td><td align="left" colspan="1" rowspan="1">820.522099</td><td align="left" colspan="1" rowspan="1">1106.237452</td><td align="left" colspan="1" rowspan="1">1.93E&#8201;+&#8201;03</td><td char="." align="char" colspan="1" rowspan="1">0.63110986</td></tr><tr><td align="left" colspan="1" rowspan="1">TCGA-BP-5001-01A-01R-1334-07</td><td align="left" colspan="1" rowspan="1">346.5236311</td><td align="left" colspan="1" rowspan="1">1467.218027</td><td align="left" colspan="1" rowspan="1">1.81E&#8201;+&#8201;03</td><td char="." align="char" colspan="1" rowspan="1">0.64389096</td></tr><tr><td align="left" colspan="1" rowspan="1">TCGA-CZ-5461-01A-01R-1503-07</td><td align="left" colspan="1" rowspan="1">1211.281392</td><td align="left" colspan="1" rowspan="1">1758.295848</td><td align="left" colspan="1" rowspan="1">2.97E&#8201;+&#8201;03</td><td char="." align="char" colspan="1" rowspan="1">0.50545537</td></tr><tr><td align="left" colspan="1" rowspan="1">TCGA-CZ-5456-01A-01R-1503-07</td><td align="left" colspan="1" rowspan="1">894.1233338</td><td align="left" colspan="1" rowspan="1">1949.159467</td><td align="left" colspan="1" rowspan="1">2.84E&#8201;+&#8201;03</td><td char="." align="char" colspan="1" rowspan="1">0.52136365</td></tr><tr><td align="left" colspan="1" rowspan="1">TCGA-B0-4706-01A-01R-1503-07</td><td align="left" colspan="1" rowspan="1">383.0246261</td><td align="left" colspan="1" rowspan="1">1236.646795</td><td align="left" colspan="1" rowspan="1">1.62E&#8201;+&#8201;03</td><td char="." align="char" colspan="1" rowspan="1">0.66542285</td></tr></tbody></table><table-wrap-foot><p> Elevated estimatescores indicate a diminished level of tumor purity within the sample</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec26"><title>Immune cell infiltration, correlation, and therapeutic analysis</title><p id="Par40">Using an immune cell infiltration algorithm, the immune cell composition of individual samples was determined, as shown in Table&#160;<xref rid="Tab6" ref-type="table">6</xref>, where rows represent sample names and columns denote immune cell types, with values indicating the normalized relative proportions of immune cells per sample, ensuring the sum equals 1. Immune cell correlation analysis (Fig.&#160;<xref rid="Fig8" ref-type="fig">8</xref>A) identified 13 immune cell types significantly correlated with hsa-miR-21-5p. Among these, seven cell types&#8212;M0 macrophages, regulatory T cells, memory-activated CD4&#8201;+&#8201;T cells, M2 macrophages, activated mast cells, neutrophils, and T follicular helper cells&#8212;exhibited statistically significant positive correlations (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05) with hsa-miR-21-5p expression, suggesting a positive regulatory relationship. Conversely, six cell types&#8212;activated dendritic cells, resting dendritic cells, resting NK cells, monocytes, M1 macrophages, and resting mast cells&#8212;showed significant negative correlations (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05), indicating a negative regulatory association with hsa-miR-21-5p expression. Within the immunotherapy study framework, distinct responses to immune treatment were observed between high and low hsa-miR-21-5p expression groups. As illustrated in Fig.&#160;<xref rid="Fig8" ref-type="fig">8</xref>B, comparative analysis revealed statistically significant differences (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05) in scores, with the high-expression group exhibiting higher scores, reflecting an increased likelihood of immune evasion and reduced immunotherapy efficacy. These findings underscore the role of hsa-miR-21-5p in modulating immune cell dynamics and its potential impact on immunotherapy outcomes.</p><p id="Par41">
<table-wrap id="Tab6" position="float" orientation="portrait"><label>Table 6</label><caption><p>The rows represent the names of the samples, and the columns represent the names of immune cells</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Mixture</th><th align="left" colspan="1" rowspan="1">Plasma cells</th><th align="left" colspan="1" rowspan="1">T cells CD8</th><th align="left" colspan="1" rowspan="1">T cells CD4 memory resting</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">TCGA-A3-3387-11A-01R-1541-07</td><td align="left" colspan="1" rowspan="1">1.84E&#8211; 02</td><td char="." align="char" colspan="1" rowspan="1">0.004998974</td><td char="." align="char" colspan="1" rowspan="1">0.185502546</td></tr><tr><td align="left" colspan="1" rowspan="1">TCGA-CW-5584-11A-01R-1541-07</td><td align="left" colspan="1" rowspan="1">2.86E&#8211; 02</td><td char="." align="char" colspan="1" rowspan="1">0.084288531</td><td char="." align="char" colspan="1" rowspan="1">0.189258373</td></tr><tr><td align="left" colspan="1" rowspan="1">TCGA-B0-5699-11A-01R-1541-07</td><td align="left" colspan="1" rowspan="1">2.62E&#8211; 02</td><td char="." align="char" colspan="1" rowspan="1">0.018009222</td><td char="." align="char" colspan="1" rowspan="1">0.19177824</td></tr><tr><td align="left" colspan="1" rowspan="1">TCGA-CZ-5984-11A-01R-1672-07</td><td align="left" colspan="1" rowspan="1">3.64E&#8211; 02</td><td char="." align="char" colspan="1" rowspan="1">0.043796075</td><td char="." align="char" colspan="1" rowspan="1">0.288233383</td></tr><tr><td align="left" colspan="1" rowspan="1">TCGA-B0-5709-11A-01R-1541-07</td><td align="left" colspan="1" rowspan="1">3.87E&#8211; 03</td><td char="." align="char" colspan="1" rowspan="1">0.068253478</td><td char="." align="char" colspan="1" rowspan="1">0.271467962</td></tr><tr><td align="left" colspan="1" rowspan="1">TCGA-CZ-5986-11A-01R-1672-07</td><td align="left" colspan="1" rowspan="1">1.90E&#8211; 02</td><td char="." align="char" colspan="1" rowspan="1">0.013712961</td><td char="." align="char" colspan="1" rowspan="1">0.282087046</td></tr><tr><td align="left" colspan="1" rowspan="1">TCGA-CJ-5689-11A-01R-1541-07</td><td align="left" colspan="1" rowspan="1">9.23E&#8211; 02</td><td char="." align="char" colspan="1" rowspan="1">0.115466424</td><td char="." align="char" colspan="1" rowspan="1">0.135952015</td></tr><tr><td align="left" colspan="1" rowspan="1">TCGA-CZ-5985-11A-01R-1672-07</td><td align="left" colspan="1" rowspan="1">1.53E&#8211; 03</td><td char="." align="char" colspan="1" rowspan="1">0.019557736</td><td char="." align="char" colspan="1" rowspan="1">0.198793238</td></tr><tr><td align="left" colspan="1" rowspan="1">TCGA-CZ-4865-11A-01R-1503-07</td><td align="left" colspan="1" rowspan="1">1.26E&#8211; 03</td><td char="." align="char" colspan="1" rowspan="1">0.099786886</td><td char="." align="char" colspan="1" rowspan="1">0.214005764</td></tr><tr><td align="left" colspan="1" rowspan="1">TCGA-CZ-5470-11A-01R-1503-07</td><td align="left" colspan="1" rowspan="1">1.59E&#8211; 02</td><td char="." align="char" colspan="1" rowspan="1">0.029854695</td><td char="." align="char" colspan="1" rowspan="1">0.340393439</td></tr></tbody></table><table-wrap-foot><p>The values inside the table indicate the relative content of each immune cell in each sample (the content is normalized so that the sum of various immune cells is 1 for each sample)</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec27"><title>Drug sensitivity and sensitivity differential analysis</title><p id="Par42">The drug sensitivity scores, displayed in Table&#160;<xref rid="Tab7" ref-type="table">7</xref>, feature sample names in rows and drug names in columns, with values indicating corresponding drug sensitivity ratings, where lower scores reflect increased susceptibility to the respective medication. Changes in drug sensitivity were examined between groups with high and low hsa-miR-21-5p expression levels. In Fig.&#160;<xref rid="Fig8" ref-type="fig">8</xref>C, the horizontal axis represents miRNA expression grouping, while the vertical axis denotes drug sensitivity scores. Visual analysis revealed statistically significant disparities (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05) in drug sensitivity scores between the two groups, with the high-expression group showing lower scores, indicating increased susceptibility to the administered medication. Notably, specific drugs, including etoposide, vincristine, daporinad, quemtricitinib, and luminespib, exhibited discernible variations in the high-expression group, resulting in lower sensitivity ratings. These findings suggest a correlation between elevated hsa-miR-21-5p expression and heightened sensitivity to the aforementioned medications, highlighting its potential role in influencing drug response.</p><p id="Par43">
<fig id="Fig8" position="float" orientation="portrait"><label>Fig. 8</label><caption><p>Analysis of immunotherapy and drug sensitivity. <bold>A</bold> A positive regulatory association exists between hsa-miR-21-5p and seven immune cells, while a negative regulatory connection is observed between hsa-miR-21-5p and six immune cells. <bold>B</bold> Significant differences in immune therapy outcomes are evident between the high and low expression groups of hsa-miR-21-5p, with a p-value of less than 0.05. <bold>C</bold> Differential analysis of drug sensitivity reveals significant differences when <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1700" position="float" orientation="portrait" xlink:href="12672_2025_3263_Fig8_HTML.jpg"/></fig>
</p><p id="Par44">
<table-wrap id="Tab7" position="float" orientation="portrait"><label>Table 7</label><caption><p>In the table, sample names are listed in rows, drug names are listed in columns, and the values within the table represent the respective drug sensitivity scores</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">Camptothecin_1003</th><th align="left" colspan="1" rowspan="1">Vinblastine_1004</th><th align="left" colspan="1" rowspan="1">Cisplatin_1005</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">TCGA-CJ-4639</td><td char="." align="char" colspan="1" rowspan="1">0.047085814</td><td char="." align="char" colspan="1" rowspan="1">0.020254012</td><td align="left" colspan="1" rowspan="1">25.33716691</td></tr><tr><td align="left" colspan="1" rowspan="1">TCGA-BP-4964</td><td char="." align="char" colspan="1" rowspan="1">0.12292948</td><td char="." align="char" colspan="1" rowspan="1">0.033648979</td><td align="left" colspan="1" rowspan="1">49.6397594</td></tr><tr><td align="left" colspan="1" rowspan="1">TCGA-A3-A8OW</td><td char="." align="char" colspan="1" rowspan="1">0.040105077</td><td char="." align="char" colspan="1" rowspan="1">0.008335073</td><td align="left" colspan="1" rowspan="1">9.164759848</td></tr><tr><td align="left" colspan="1" rowspan="1">TCGA-BP-4983</td><td char="." align="char" colspan="1" rowspan="1">0.029341232</td><td char="." align="char" colspan="1" rowspan="1">0.002656481</td><td align="left" colspan="1" rowspan="1">3.316352032</td></tr><tr><td align="left" colspan="1" rowspan="1">TCGA-B0-5698</td><td char="." align="char" colspan="1" rowspan="1">0.055302971</td><td char="." align="char" colspan="1" rowspan="1">0.033993868</td><td align="left" colspan="1" rowspan="1">12.68280256</td></tr><tr><td align="left" colspan="1" rowspan="1">TCGA-BP-5186</td><td char="." align="char" colspan="1" rowspan="1">0.163000388</td><td char="." align="char" colspan="1" rowspan="1">0.035048006</td><td align="left" colspan="1" rowspan="1">45.41834252</td></tr><tr><td align="left" colspan="1" rowspan="1">TCGA-BP-5001</td><td char="." align="char" colspan="1" rowspan="1">0.145046428</td><td char="." align="char" colspan="1" rowspan="1">0.047670448</td><td align="left" colspan="1" rowspan="1">102.8878823</td></tr><tr><td align="left" colspan="1" rowspan="1">TCGA-CZ-5461</td><td char="." align="char" colspan="1" rowspan="1">0.066923638</td><td char="." align="char" colspan="1" rowspan="1">0.011501669</td><td align="left" colspan="1" rowspan="1">22.22390088</td></tr><tr><td align="left" colspan="1" rowspan="1">TCGA-CZ-5456</td><td char="." align="char" colspan="1" rowspan="1">0.1121144</td><td char="." align="char" colspan="1" rowspan="1">0.021023132</td><td align="left" colspan="1" rowspan="1">21.38445346</td></tr><tr><td align="left" colspan="1" rowspan="1">TCGA-B0-4706</td><td char="." align="char" colspan="1" rowspan="1">0.085607545</td><td char="." align="char" colspan="1" rowspan="1">0.012184964</td><td align="left" colspan="1" rowspan="1">36.00619402</td></tr></tbody></table><table-wrap-foot><p>Lower scores suggest greater sensitivity of the sample to the corresponding drug</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec28"><title>Validation of the predicted target genes</title><p id="Par45">We further used qPCR to validate the top 10 predicted genes, and the results revealed significant differences in the expression of the predicted hsa-miR-21-5p target genes between tumour tissues and adjacent nontumor tissues (Fig.&#160;<xref rid="Fig9" ref-type="fig">9</xref>).</p><p id="Par46">
<fig id="Fig9" position="float" orientation="portrait"><label>Fig. 9</label><caption><p>Expression of target genes of hsa-miR-21-5p. The relative miRNAs expression levels of the top predicted target genes of hsa-miR-21-5p were validated in tumor tissues compared to adjacent normal tissues. The expression levels of (A) YOD1, (B) KRIT1, (C) FASLG, (D) ZNF367, (E) ST3GAL6-F, (F) TIMP3, (G) IL-12A, (H) GATAD2B, and (I) GTPBP10 were significantly differentially expressed. Data are presented as mean &#177; SD. *p &lt; 0.05, **p &lt; 0.01, ***p &lt; 0.001.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1832" position="float" orientation="portrait" xlink:href="12672_2025_3263_Fig9_HTML.jpg"/></fig>
</p></sec></sec><sec id="Sec29"><title>Discussion</title><p id="Par47">Hsa-miR-21-5p is a well-established oncomiR, reported to be overexpressed in diverse malignancies such as breast cancer [<xref ref-type="bibr" rid="CR38">38</xref>], nasopharyngeal carcinoma [<xref ref-type="bibr" rid="CR41">41</xref>], and colorectal cancer [<xref ref-type="bibr" rid="CR44">44</xref>], and is often considered a valuable biomarker of tumor progression [<xref ref-type="bibr" rid="CR45">45</xref>]. However, the involvement of hsa-miR-21-5p in ccRCC remains poorly understood. Therefore, our study aimed to investigate the impact and underlying processes of hsa-miR-21-5p in ccRCC. In this study, we examined hsa-miR-21-5p expression in ccRCC. We sought to elucidate its biological roles, intending to provide insights into its potential utility as both a biomarker and a therapeutic target.</p><p id="Par48">In this study, we found that miR-21-5p expression is markedly higher in ccRCC tissues than in normal kidney, confirming prior observations. Consistent with these reports, our PCR validation showed robust overexpression of miR-21-5p in tumor samples [<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR47">47</xref>]. The persistent elevation of miR-21-5p suggests it contributes to the aggressive phenotype of ccRCC. Such dysregulation may arise from multiple factors, including the frequent genetic and epigenetic alterations in ccRCC (e.g. VHL loss and downstream HIF signaling), as well as aberrant activation of signaling pathways common to this cancer.</p><p id="Par49">Functionally, miR-21-5p behaves as an oncogenic microRNA in ccRCC. Previous studies (and our model) indicate that increased miR-21-5p levels promote tumor cell proliferation, migration, invasion and angiogenesis while inhibiting apoptosis. These effects are characteristic of oncomiRs and help explain the link between miR-21-5p and tumor progression. Indeed, high miR-21-5p expression has been correlated with advanced stage, higher grade, and worse patient survival in ccRCC [<xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR49">49</xref>]. Clinically, our risk model and external data suggest that miR-21-5p can serve as a prognostic biomarker for ccRCC, aiding in patient stratification and guiding therapy decisions. In silico target predictions highlighted involvement of miR-21-5p in calcium ion transport and the cGMP&#8211;PKG signaling pathway [<xref ref-type="bibr" rid="CR50">50</xref>], although these require experimental validation. Notably, gene set enrichment analysis (GSEA) of our risk signature revealed that fatty acid metabolism, glycolysis/gluconeogenesis, and PPAR signaling were enriched in the low-risk (lower miR-21-5p) group. Given that obesity is a known risk factor for ccRCC [<xref ref-type="bibr" rid="CR51">51</xref>], these findings suggest that lipid metabolic processes intersect with miR-21-5p&#8211;driven tumor biology.</p><p id="Par53">Indeed, ccRCC is now recognized as a paradigmatic <italic toggle="yes">metabolically reprogrammed</italic> tumor [<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR52">52</xref>]. This cancer displays global alterations in energy metabolism to meet its anabolic and bioenergetic needs. The prototypical Warburg effect &#8211; a shift from OxPhos to glycolysis even under normoxia &#8211; is especially pronounced in ccRCC [<xref ref-type="bibr" rid="CR53">53</xref>]. Loss of VHL function leads to constitutive HIF-&#945; activation, which in turn upregulates glucose transporters and glycolytic enzymes. For example, HIF-1&#945; drives transcription of GLUT1, hexokinase (HK) and LDH-A, while repressing pyruvate dehydrogenase (via PDK1) [<xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR55">55</xref>]. Recent studies further indicate that miR-21-5p directly targets HK2 and LDHA, key enzymes in glycolysis, thereby amplifying the Warburg effect [<xref ref-type="bibr" rid="CR53">53</xref>]. The net result is that pyruvate is preferentially converted to lactate rather than entering the TCA cycle. Consistent with this, mitochondrial respiration is suppressed in ccRCC cells, and accumulating TCA intermediates (e.g. succinate, fumarate) have been noted [<xref ref-type="bibr" rid="CR56">56</xref>]. In parallel, lipid metabolism is profoundly altered: ccRCC cells characteristically accumulate abundant intracellular lipid droplets, giving the classic clear-cell appearance. These droplets (rich in triglycerides and cholesterol esters) serve as energy stores and membrane precursors, reflecting dysregulated fatty acid synthesis and storage in ccRCC [<xref ref-type="bibr" rid="CR57">57</xref>]. Notably, miR-21-5p inhibits fatty acid oxidation by downregulating CPT1A, a rate-limiting enzyme in mitochondrial &#946;-oxidation [<xref ref-type="bibr" rid="CR58">58</xref>], further entrenching the lipid-dependent phenotype. In summary, genetic lesions in ccRCC rewire glucose and lipid pathways (via VHL/HIF, mTOR, PI3K-Akt, and other axes) to promote glycolysis and lipid anabolism.</p><p id="Par54">In this metabolic setting, miR-21-5p itself may act as a modulator of cellular metabolism. Emerging evidence indicates that miR-21-5p can shift the balance between glycolysis and fatty acid oxidation. In cultured cells, miR-21-5p was found to target PPAR&#945;, a key regulator of lipid metabolism, thereby altering the expression of genes involved in fatty acid oxidation and glycolysis. Experimentally, overexpression of miR-21-5p attenuated cellular lipid uptake and reduced lipid content, while its inhibition had the opposite effect. Moreover, modulation of miR-21-5p levels changed mitochondrial function: both overexpression and knockdown of miR-21-5p increased basal respiration, but overexpression blunted the oxidative response to lipid substrates and shifted cells toward glycolytic metabolism [<xref ref-type="bibr" rid="CR59">59</xref>]. These results suggest that high miR-21-5p can promote a metabolic phenotype characterized by lower reliance on fatty acid oxidation and greater dependence on glycolysis. By analogy, in ccRCC a similar mechanism could reinforce the Warburg phenotype: elevated miR-21-5p might drive glycolytic flux while dampening oxidative lipid metabolism, fitting with our GSEA observation that low miR-21-5p (low-risk) tumors are enriched for fatty acid and PPAR pathways. Thus, miR-21-5p upregulation may help sustain the characteristic glucose-centric, lipogenic metabolism of ccRCC.</p><p id="Par55">In addition to metabolic effects, miR-21-5p appears to influence the immune landscape of ccRCC. The ccRCC tumor microenvironment (TME) is highly immunogenic: tumors are often densely infiltrated by immune cells [<xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR61">61</xref>], including CD8^+ T cells, macrophages and B cells [<xref ref-type="bibr" rid="CR62">62</xref>]. Paradoxically, these infiltrates coexist with immune evasion, making ccRCC responsive to but also capable of resisting immunotherapy. This immune-rich milieu is paradoxically associated with immune evasion, as tumors exploit metabolic competition and checkpoint pathways to suppress effector responses [<xref ref-type="bibr" rid="CR60">60</xref>]. High miR-21-5p may contribute to this immunosuppressive microenvironment. For instance, miR-21-5p upregulation in ccRCC correlates with increased M2 macrophage infiltration and reduced CD8&#8201;+&#8201;T cell activity [<xref ref-type="bibr" rid="CR46">46</xref>]. Mechanistically, miR-21-5p promotes PD-L1 expression by targeting PTEN, thereby enabling immune checkpoint activation [<xref ref-type="bibr" rid="CR63">63</xref>]. Additionally, Wang et al. identified a miR-21-5p/PRKCE axis that alters cytokine secretion (e.g., IL-10, TGF-&#946;), fostering a pro-tumorigenic inflammatory state [<xref ref-type="bibr" rid="CR46">46</xref>]. These findings align with clinical observations that high miR-21-5p levels predict poorer response to anti-PD-1 therapy, underscoring its role in immune resistance. A defining feature of the ccRCC TME is <italic toggle="yes">immunoflogosis</italic> &#8211; an intense, dysregulated inflammatory state that can both attack and inadvertently support the tumor. For example, Ranieri et al. showed that PTX3-driven complement activation in ccRCC tissue leads to C1q binding and release of anaphylatoxins C3a and C5a, fueling angiogenesis and creating a pro-tumorigenic inflammatory milieu. Initially, such inflammation may suppress tumor growth, but if chronic it &#8220;enriches the tumor microenvironment with pro-inflammatory cytokines and growth factors&#8221; that paradoxically promote cancer progression [<xref ref-type="bibr" rid="CR64">64</xref>]. Indeed, ccRCC subtypes with marked immunoflogosis often exhibit an &#8220;immune-silent&#8221; profile &#8211; e.g. high M2-type macrophage infiltration and low effector T cell activity [<xref ref-type="bibr" rid="CR65">65</xref>].</p><p id="Par56">High miR-21-5p may contribute to this immunosuppressive microenvironment. Recent analyses of ccRCC (KIRC) datasets have linked miR-21-5p to immune cell infiltration. In particular, Wang et al. identified a miR-21-5p/PRKCE regulatory axis: tumors with elevated miR-21-5p and concomitantly low PRKCE showed altered patterns of immune infiltration, and PRKCE expression was strongly associated with immune cell content [<xref ref-type="bibr" rid="CR46">46</xref>]. This suggests that miR-21-5p may indirectly modulate tumor immunity through downstream targets (like PRKCE) that influence leukocyte recruitment or activation. Moreover, other work indicates that miR-21 signaling can affect cytokine networks and immune checkpoints in tumor cells. Taken together, our data and the literature imply that miR-21-5p upregulation in ccRCC not only drives intrinsic tumor growth, but also skews the TME toward immune evasion. This could help explain our finding that high miR-21-5p levels predict poorer response to immunotherapy.</p><p id="Par545">However, additional investigations are needed to comprehensively understand the specific function of hsa-miR-21-5p in the development of ccRCC. The identification of other target genes and signalling pathways modulated by hsa-miR-21-5p will enhance our understanding of its biological roles in the context of ccRCC [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR51">51</xref>]. Furthermore, it is imperative to perform in vivo research and validate preclinical models to substantiate the potential therapeutic efficacy of targeting hsa-miR-21-5p for the treatment of ccRCC. Additional research is necessary to elucidate the specific mechanisms by which hsa-miR-21-5p operates and to confirm its clinical utility as both a biomarker and a target for therapy in the setting of ccRCC.</p><p id="Par556">Few prognostic miRNA models have been established for KIRC. Compared with previous models, our model uses more statistical methods to obtain prognostic miRNAs. Under this model, the Kaplan&#8211;Meier curve revealed that the low-risk group had a better survival rate. ROC analysis revealed that this risk model contributed to predicting KIRC patient prognosis. In addition, clinical features were integrated into this miRNA model in KIRC to construct a nomogram, which is the first report of such a model. Furthermore, miRNA expression was examined in KIRC tissues, and these findings should be confirmed in studies with larger sample sizes. In the future, more clinical databases should be used to verify the accuracy of the miRNA model.</p><p id="Par567">In conclusion, our study reinforces the view of miR-21-5p as a key oncogenic driver in ccRCC. We have confirmed that miR-21-5p is upregulated in tumors and associated with adverse pathological features and outcomes. Importantly, we also highlight new dimensions of miR-21-5p function in ccRCC: its likely involvement in metabolic reprogramming and immune modulation. MiR-21-5p may promote ccRCC progression by enhancing glycolysis and lipid accumulation &#8211; core hallmarks of this cancer &#8211; as well as by shaping a pro-tumorigenic inflammatory milieu. These insights align with our functional predictions (e.g. PPAR and glycolysis pathways) and with emerging evidence of miR-21&#8211;mediated metabolic and immunological effects [<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR59">59</xref>]. Going forward, it will be critical to identify the specific targets of miR-21-5p in ccRCC (for example within metabolic and cytokine pathways) and to test whether manipulating miR-21-5p can re-sensitize tumors to therapy. In vivo validation of miR-21-5p inhibition &#8211; and its impact on tumor metabolism and immune escape &#8211; should be a priority. Such studies will determine whether miR-21-5p is not only a biomarker but also a viable therapeutic target in ccRCC.</p></sec><sec id="Sec30"><title>Conclusions</title><p id="Par57">In this work, a comprehensive investigation was undertaken to examine the biological functions of hsa-miR-21-5p in ccRCC. These findings revealed the potential of hsa-miR-21-5p as an independent prognostic factor and diagnostic biomarker for individuals with ccRCC. In addition, our research investigated the intricate immune evasion processes in ccRCC and analysed drug sensitivity. These findings provide valuable insights into potential avenues for immune-based therapies in ccRCC patients, particularly those exhibiting increased hsa-miR-21-5p expression levels. In conclusion, our research enhances our understanding of the diverse functions of hsa-miR-21-5p in ccRCC, including its involvement in tumour formation, evasion of the immune system, and response to therapeutic drugs.</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Mu-Yang Xu, Xu Wang, and Shao-yu Yue have the same contributions.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We thank TCGA and GEO databases for providing a platform for data sharing.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>The authors confirm contribution to the paper as follows: Conceptualization, Muyang Xu and Chaozhao Liang; software, Mu-Yang Xu, Xu-Wang, Shao-yu Yue, Lei Chen, Qing-Wei Meng, Rong-Rong Li, Ke Zhang and Xiao-Xin Bai; validation, Mu-Yang Xu, Xu-Wang, Shao-yu Yue, Lei Chen, Qing-Wei Meng, Rong-Rong Li, Ke Zhang and Xiao-Xin Bai; formal analysis, Mu-Yang Xu, Xu-Wang, Shao-yu Yue, Lei Chen, Qing-Wei Meng, Rong-Rong Li, Ke Zhang and Xiao-Xin Bai; resources, Mu-Yang Xu, Xu-Wang, Shao-yu Yue, Lei Chen, Qing-Wei Meng, Rong-Rong Li, Ke Zhang and Xiao-Xin Bai; writing&#8212;original draft preparation, Chaozhao Liang, Yu Guan, and Lingfan Xu; writing&#8212;review and editing, Muyang Xu and Chaozhao Liang; visualization, Muyang Xu and Chaozhao Liang; supervision, Chaozhao Liang, Yu Guan, and Lingfan Xu; project administration, Chaozhao Liang, Yu Guan, and Lingfan Xu; funding acquisition, Chaozhao Liang, Yu Guan, and Lingfan Xu. All authors reviewed the results and approved the final version of the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This research was funded by the National Natural Science Fund of China (82370776).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The datasets analyzed during the current study are publicly available from The Cancer Genome Atlas (TCGA) database (https://portal.gdc.cancer.gov/). The raw data can be accessed upon registration and compliance with data use policies. All processed data and codes used in this study are available from the corresponding author upon reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar2"><title>Ethics approval</title><p id="Par58">All patients gave written informed consent for using clinical data in the study in accordance with the Declaration of Helsinki. The study has been approved by the Ethics Committee of the First Affiliated Hospital of Anhui Medical University(PJ2024-10-72).</p></notes><notes id="FPar3"><title>Consent to participate</title><p id="Par59">Informed consent was obtained from all participants involved in the study.</p></notes><notes id="FPar4"><title>Consent to publish</title><p id="Par60">Informed consent was obtained from all participants for publication of the research findings.</p></notes><notes id="FPar1" notes-type="COI-statement"><title>Competing Interests</title><p id="Par61">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hsieh</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Purdue</surname><given-names>MP</given-names></name><name name-style="western"><surname>Signoretti</surname><given-names>S</given-names></name><etal/></person-group><article-title>Renal cell carcinoma[J]</article-title><source>Nat Rev Dis Primers</source><year>2017</year><volume>3</volume><fpage>17009</fpage><pub-id pub-id-type="doi">10.1038/nrdp.2017.9</pub-id><pub-id pub-id-type="pmid">28276433</pub-id><pub-id pub-id-type="pmcid">PMC5936048</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Hsieh JJ, Purdue MP, Signoretti S, et al. Renal cell carcinoma. Nat Rev Dis Primers. 2017;3:17009.<pub-id pub-id-type="pmid">28276433</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrdp.2017.9</pub-id><pub-id pub-id-type="pmcid">PMC5936048</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hsieh</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Purdue</surname><given-names>MP</given-names></name><name name-style="western"><surname>Signoretti</surname><given-names>S</given-names></name><etal/></person-group><article-title>Renal cell carcinoma[J]</article-title><source>Nat Reviews Disease Primers</source><year>2017</year><volume>3</volume><issue>1</issue><fpage>17009</fpage><pub-id pub-id-type="doi">10.1038/nrdp.2017.9</pub-id><pub-id pub-id-type="pmid">28276433</pub-id><pub-id pub-id-type="pmcid">PMC5936048</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Hsieh JJ, Purdue MP, Signoretti S, et al. Renal cell carcinoma. Nat Rev Disease Primers. 2017;3(1):17009.<pub-id pub-id-type="pmid">28276433</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrdp.2017.9</pub-id><pub-id pub-id-type="pmcid">PMC5936048</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jemal</surname><given-names>A</given-names></name><name name-style="western"><surname>Siegel</surname><given-names>R</given-names></name><name name-style="western"><surname>Ward</surname><given-names>E</given-names></name><etal/></person-group><article-title>Cancer statistics, 2008[J]</article-title><source>CA Cancer J Clin</source><year>2008</year><volume>58</volume><issue>2</issue><fpage>71</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">18287387</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/CA.2007.0010</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58(2):71&#8211;96.<pub-id pub-id-type="pmid">18287387</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/CA.2007.0010</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferlay</surname><given-names>J</given-names></name><name name-style="western"><surname>Colombet</surname><given-names>M</given-names></name><name name-style="western"><surname>Soerjomataram</surname><given-names>I</given-names></name><etal/></person-group><article-title>Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods[J]</article-title><source>Int J Cancer</source><year>2019</year><volume>144</volume><issue>8</issue><fpage>1941</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1002/ijc.31937</pub-id><pub-id pub-id-type="pmid">30350310</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941&#8211;53.<pub-id pub-id-type="pmid">30350310</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ijc.31937</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meng</surname><given-names>K</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name><name name-style="western"><surname>Cui</surname><given-names>X</given-names></name></person-group><article-title>Three LHPP gene-targeting co-expressed MicroRNAs (microRNA-765, microRNA-21, and microRNA-144) promote proliferation, epithelial-mesenchymal transition, invasion, and are independent prognostic biomarkers in renal cell carcinomas patients[J]</article-title><source>J Clin Lab Anal</source><year>2021</year><volume>35</volume><issue>12</issue><fpage>e24077</fpage><pub-id pub-id-type="doi">10.1002/jcla.24077</pub-id><pub-id pub-id-type="pmid">34699621</pub-id><pub-id pub-id-type="pmcid">PMC8649365</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Meng K, Li Z, Cui X. Three LHPP gene-targeting co-expressed MicroRNAs (microRNA-765, microRNA-21, and microRNA-144) promote proliferation, epithelial-mesenchymal transition, invasion, and are independent prognostic biomarkers in renal cell carcinomas patients. J Clin Lab Anal. 2021;35(12):e24077.<pub-id pub-id-type="pmid">34699621</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcla.24077</pub-id><pub-id pub-id-type="pmcid">PMC8649365</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wolf</surname><given-names>MM</given-names></name><name name-style="western"><surname>Kimryn Rathmell</surname><given-names>W</given-names></name><name name-style="western"><surname>Beckermann</surname><given-names>KE</given-names></name></person-group><article-title>Modeling clear cell renal cell carcinoma and therapeutic implications[J]</article-title><source>Oncogene</source><year>2020</year><volume>39</volume><issue>17</issue><fpage>3413</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1038/s41388-020-1234-3</pub-id><pub-id pub-id-type="pmid">32123314</pub-id><pub-id pub-id-type="pmcid">PMC7194123</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Wolf MM, Kimryn Rathmell W, Beckermann KE. Modeling clear cell renal cell carcinoma and therapeutic implications. Oncogene. 2020;39(17):3413&#8211;26.<pub-id pub-id-type="pmid">32123314</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41388-020-1234-3</pub-id><pub-id pub-id-type="pmcid">PMC7194123</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dabestani</surname><given-names>S</given-names></name><name name-style="western"><surname>Thorstenson</surname><given-names>A</given-names></name><name name-style="western"><surname>Lindblad</surname><given-names>P</given-names></name><etal/></person-group><article-title>Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based study[J]</article-title><source>World J Urol</source><year>2016</year><volume>34</volume><issue>8</issue><fpage>1081</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1007/s00345-016-1773-y</pub-id><pub-id pub-id-type="pmid">26847337</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Dabestani S, Thorstenson A, Lindblad P, et al. Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based study. World J Urol. 2016;34(8):1081&#8211;6.<pub-id pub-id-type="pmid">26847337</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00345-016-1773-y</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Turajlic</surname><given-names>S</given-names></name><name name-style="western"><surname>Swanton</surname><given-names>C</given-names></name><name name-style="western"><surname>Boshoff</surname><given-names>C</given-names></name></person-group><article-title>Kidney cancer: the next decade[J]</article-title><source>J Exp Med</source><year>2018</year><volume>215</volume><issue>10</issue><fpage>2477</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1084/jem.20181617</pub-id><pub-id pub-id-type="pmid">30217855</pub-id><pub-id pub-id-type="pmcid">PMC6170181</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Turajlic S, Swanton C, Boshoff C. Kidney cancer: the next decade. J Exp Med. 2018;215(10):2477&#8211;9.<pub-id pub-id-type="pmid">30217855</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.20181617</pub-id><pub-id pub-id-type="pmcid">PMC6170181</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><collab>Comprehensive molecular characterization</collab></person-group><article-title>Of clear cell renal cell carcinoma[J]</article-title><source>Nature</source><year>2013</year><volume>499</volume><issue>7456</issue><fpage>43</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1038/nature12222</pub-id><pub-id pub-id-type="pmid">23792563</pub-id><pub-id pub-id-type="pmcid">PMC3771322</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Comprehensive molecular characterization. Of clear cell renal cell carcinoma. Nature. 2013;499(7456):43&#8211;9.<pub-id pub-id-type="pmid">23792563</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature12222</pub-id><pub-id pub-id-type="pmcid">PMC3771322</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>G</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><etal/></person-group><article-title>A new prognostic risk model based on autophagy-related genes in kidney renal clear cell carcinoma[J]</article-title><source>Bioengineered</source><year>2021</year><volume>12</volume><issue>1</issue><fpage>7805</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1080/21655979.2021.1976050</pub-id><pub-id pub-id-type="pmid">34636718</pub-id><pub-id pub-id-type="pmcid">PMC8806698</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Wu G, Xu Y, Zhang H, et al. A new prognostic risk model based on autophagy-related genes in kidney renal clear cell carcinoma. Bioengineered. 2021;12(1):7805&#8211;19.<pub-id pub-id-type="pmid">34636718</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/21655979.2021.1976050</pub-id><pub-id pub-id-type="pmcid">PMC8806698</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ljungberg</surname><given-names>B</given-names></name><name name-style="western"><surname>Albiges</surname><given-names>L</given-names></name><name name-style="western"><surname>Abu-Ghanem</surname><given-names>Y</given-names></name><etal/></person-group><article-title>European association of urology guidelines on renal cell carcinoma: the 2019 Update[J]</article-title><source>Eur Urol</source><year>2019</year><volume>75</volume><issue>5</issue><fpage>799</fpage><lpage>810</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2019.02.011</pub-id><pub-id pub-id-type="pmid">30803729</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Ljungberg B, Albiges L, Abu-Ghanem Y, et al. European association of urology guidelines on renal cell carcinoma: the 2019 Update. Eur Urol. 2019;75(5):799&#8211;810.<pub-id pub-id-type="pmid">30803729</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eururo.2019.02.011</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Escudier</surname><given-names>B</given-names></name><name name-style="western"><surname>Porta</surname><given-names>C</given-names></name><name name-style="western"><surname>Schmidinger</surname><given-names>M</given-names></name><etal/></person-group><article-title>Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up[J]</article-title><source>Ann Oncol</source><year>2016</year><volume>27</volume><issue>suppl 5</issue><fpage>v58</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdw328</pub-id><pub-id pub-id-type="pmid">27664262</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v58&#8211;68.<pub-id pub-id-type="pmid">27664262</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/annonc/mdw328</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>KG</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>S</given-names></name><name name-style="western"><surname>Goel</surname><given-names>S</given-names></name></person-group><article-title>Immunotherapy: incorporation in the evolving paradigm of renal cancer management and future prospects[J]</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><issue>10</issue><fpage>17313</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.14388</pub-id><pub-id pub-id-type="pmid">28061473</pub-id><pub-id pub-id-type="pmcid">PMC5370043</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Liu KG, Gupta S, Goel S. Immunotherapy: incorporation in the evolving paradigm of renal cancer management and future prospects. Oncotarget. 2017;8(10):17313&#8211;27.<pub-id pub-id-type="pmid">28061473</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/oncotarget.14388</pub-id><pub-id pub-id-type="pmcid">PMC5370043</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ljungberg</surname><given-names>B</given-names></name><name name-style="western"><surname>Albiges</surname><given-names>L</given-names></name><name name-style="western"><surname>Abu-Ghanem</surname><given-names>Y</given-names></name><etal/></person-group><article-title>European association of urology guidelines on renal cell carcinoma: the 2022 Update[J]</article-title><source>Eur Urol</source><year>2022</year><volume>82</volume><issue>4</issue><fpage>399</fpage><lpage>410</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2022.03.006</pub-id><pub-id pub-id-type="pmid">35346519</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Ljungberg B, Albiges L, Abu-Ghanem Y, et al. European association of urology guidelines on renal cell carcinoma: the 2022 Update. Eur Urol. 2022;82(4):399&#8211;410.<pub-id pub-id-type="pmid">35346519</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eururo.2022.03.006</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Posadas</surname><given-names>EM</given-names></name><name name-style="western"><surname>Limvorasak</surname><given-names>S</given-names></name><name name-style="western"><surname>Figlin</surname><given-names>RA</given-names></name></person-group><article-title>Targeted therapies for renal cell carcinoma[J]</article-title><source>Nat Rev Nephrol</source><year>2017</year><volume>13</volume><issue>8</issue><fpage>496</fpage><lpage>511</lpage><pub-id pub-id-type="doi">10.1038/nrneph.2017.82</pub-id><pub-id pub-id-type="pmid">28691713</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Posadas EM, Limvorasak S, Figlin RA. Targeted therapies for renal cell carcinoma. Nat Rev Nephrol. 2017;13(8):496&#8211;511.<pub-id pub-id-type="pmid">28691713</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrneph.2017.82</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bex</surname><given-names>A</given-names></name><name name-style="western"><surname>Jonasch</surname><given-names>E</given-names></name><name name-style="western"><surname>Kirkali</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials[J]</article-title><source>Eur Urol</source><year>2010</year><volume>58</volume><issue>6</issue><fpage>819</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2010.08.029</pub-id><pub-id pub-id-type="pmid">20828919</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Bex A, Jonasch E, Kirkali Z, et al. Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials. Eur Urol. 2010;58(6):819&#8211;28.<pub-id pub-id-type="pmid">20828919</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eururo.2010.08.029</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lai</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tang</surname><given-names>F</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>The tumour microenvironment and metabolism in renal cell carcinoma targeted or immune therapy[J]</article-title><source>J Cell Physiol</source><year>2021</year><volume>236</volume><issue>3</issue><fpage>1616</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1002/jcp.29969</pub-id><pub-id pub-id-type="pmid">32783202</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Lai Y, Tang F, Huang Y, et al. The tumour microenvironment and metabolism in renal cell carcinoma targeted or immune therapy. J Cell Physiol. 2021;236(3):1616&#8211;27.<pub-id pub-id-type="pmid">32783202</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcp.29969</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bedke</surname><given-names>J</given-names></name><name name-style="western"><surname>Gauler</surname><given-names>T</given-names></name><name name-style="western"><surname>Gr&#252;nwald</surname><given-names>V</given-names></name><etal/></person-group><article-title>Systemic therapy in metastatic renal cell carcinoma[J]</article-title><source>World J Urol</source><year>2017</year><volume>35</volume><issue>2</issue><fpage>179</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1007/s00345-016-1868-5</pub-id><pub-id pub-id-type="pmid">27277600</pub-id><pub-id pub-id-type="pmcid">PMC5272893</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Bedke J, Gauler T, Gr&#252;nwald V, et al. Systemic therapy in metastatic renal cell carcinoma. World J Urol. 2017;35(2):179&#8211;88.<pub-id pub-id-type="pmid">27277600</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00345-016-1868-5</pub-id><pub-id pub-id-type="pmcid">PMC5272893</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gulati</surname><given-names>S</given-names></name><name name-style="western"><surname>Labaki</surname><given-names>C</given-names></name><name name-style="western"><surname>Karachaliou</surname><given-names>GS</given-names></name><etal/></person-group><article-title>First-Line treatments for metastatic clear cell renal cell carcinoma: an Ever-Enlarging Landscape[J]</article-title><source>Oncologist</source><year>2022</year><volume>27</volume><issue>2</issue><fpage>125</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1093/oncolo/oyab056</pub-id><pub-id pub-id-type="pmid">35641205</pub-id><pub-id pub-id-type="pmcid">PMC8895741</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Gulati S, Labaki C, Karachaliou GS, et al. First-Line treatments for metastatic clear cell renal cell carcinoma: an Ever-Enlarging Landscape. Oncologist. 2022;27(2):125&#8211;34.<pub-id pub-id-type="pmid">35641205</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/oncolo/oyab056</pub-id><pub-id pub-id-type="pmcid">PMC8895741</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dutcher</surname><given-names>JP</given-names></name></person-group><article-title>Recent developments in the treatment of renal cell carcinoma[J]</article-title><source>Ther Adv Urol</source><year>2013</year><volume>5</volume><issue>6</issue><fpage>338</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1177/1756287213505672</pub-id><pub-id pub-id-type="pmid">24294292</pub-id><pub-id pub-id-type="pmcid">PMC3825112</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Dutcher JP. Recent developments in the treatment of renal cell carcinoma. Ther Adv Urol. 2013;5(6):338&#8211;53.<pub-id pub-id-type="pmid">24294292</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1756287213505672</pub-id><pub-id pub-id-type="pmcid">PMC3825112</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Atkins</surname><given-names>MB</given-names></name><name name-style="western"><surname>Tannir</surname><given-names>NM</given-names></name></person-group><article-title>Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma[J]</article-title><source>Cancer Treat Rev</source><year>2018</year><volume>70</volume><fpage>127</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/j.ctrv.2018.07.009</pub-id><pub-id pub-id-type="pmid">30173085</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Atkins MB, Tannir NM. Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma. Cancer Treat Rev. 2018;70:127&#8211;37.<pub-id pub-id-type="pmid">30173085</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ctrv.2018.07.009</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Powles</surname><given-names>T</given-names></name><name name-style="western"><surname>Albiges</surname><given-names>L</given-names></name><name name-style="western"><surname>Bex</surname><given-names>A</given-names></name><etal/></person-group><article-title>ESMO clinical practice guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma[J]</article-title><source>Ann Oncol</source><year>2021</year><volume>32</volume><issue>12</issue><fpage>1511</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.annonc.2021.09.014</pub-id><pub-id pub-id-type="pmid">34597799</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Powles T, Albiges L, Bex A, et al. ESMO clinical practice guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma. Ann Oncol. 2021;32(12):1511&#8211;9.<pub-id pub-id-type="pmid">34597799</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.annonc.2021.09.014</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>J</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Sunitinib resistance in renal cell carcinoma: from molecular mechanisms to predictive biomarkers[J]</article-title><source>Drug Resist Updat</source><year>2023</year><volume>67</volume><fpage>100929</fpage><pub-id pub-id-type="doi">10.1016/j.drup.2023.100929</pub-id><pub-id pub-id-type="pmid">36739809</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Jin J, Xie Y, Zhang JS, et al. Sunitinib resistance in renal cell carcinoma: from molecular mechanisms to predictive biomarkers. Drug Resist Updat. 2023;67:100929.<pub-id pub-id-type="pmid">36739809</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drup.2023.100929</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lagos-Quintana</surname><given-names>M</given-names></name><name name-style="western"><surname>Rauhut</surname><given-names>R</given-names></name><name name-style="western"><surname>Lendeckel</surname><given-names>W</given-names></name><etal/></person-group><article-title>Identification of novel genes coding for small expressed RNAs[J]</article-title><source>Science</source><year>2001</year><volume>294</volume><issue>5543</issue><fpage>853</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1126/science.1064921</pub-id><pub-id pub-id-type="pmid">11679670</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Lagos-Quintana M, Rauhut R, Lendeckel W, et al. Identification of novel genes coding for small expressed RNAs. Science. 2001;294(5543):853&#8211;8.<pub-id pub-id-type="pmid">11679670</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.1064921</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bartel</surname><given-names>DP</given-names></name></person-group><article-title>MicroRNAs: genomics, biogenesis, mechanism, and function[J]</article-title><source>Cell</source><year>2004</year><volume>116</volume><issue>2</issue><fpage>281</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(04)00045-5</pub-id><pub-id pub-id-type="pmid">14744438</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281&#8211;97.<pub-id pub-id-type="pmid">14744438</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0092-8674(04)00045-5</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bentwich</surname><given-names>I</given-names></name></person-group><article-title>Prediction and validation of MicroRNAs and their targets[J]</article-title><source>FEBS Lett</source><year>2005</year><volume>579</volume><issue>26</issue><fpage>5904</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1016/j.febslet.2005.09.040</pub-id><pub-id pub-id-type="pmid">16214134</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Bentwich I. Prediction and validation of MicroRNAs and their targets. FEBS Lett. 2005;579(26):5904&#8211;10.<pub-id pub-id-type="pmid">16214134</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.febslet.2005.09.040</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><mixed-citation publication-type="other">Ran L, Liang J, Deng X et al. miRNAs in Prediction of prognosis in clear cell renal cell carcinoma. Biomed Res Int. 2017;2017:4832931.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2017/4832931</pub-id><pub-id pub-id-type="pmcid">PMC5748131</pub-id><pub-id pub-id-type="pmid">29392135</pub-id></mixed-citation></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mascaux</surname><given-names>C</given-names></name><name name-style="western"><surname>Laes</surname><given-names>JF</given-names></name><name name-style="western"><surname>Anthoine</surname><given-names>G</given-names></name><etal/></person-group><article-title>Evolution of MicroRNA expression during human bronchial squamous carcinogenesis[J]</article-title><source>Eur Respir J</source><year>2009</year><volume>33</volume><issue>2</issue><fpage>352</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1183/09031936.00084108</pub-id><pub-id pub-id-type="pmid">19010987</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Mascaux C, Laes JF, Anthoine G, et al. Evolution of MicroRNA expression during human bronchial squamous carcinogenesis. Eur Respir J. 2009;33(2):352&#8211;9.<pub-id pub-id-type="pmid">19010987</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1183/09031936.00084108</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosenfeld</surname><given-names>N</given-names></name><name name-style="western"><surname>Aharonov</surname><given-names>R</given-names></name><name name-style="western"><surname>Meiri</surname><given-names>E</given-names></name><etal/></person-group><article-title>MicroRNAs accurately identify cancer tissue origin[J]</article-title><source>Nat Biotechnol</source><year>2008</year><volume>26</volume><issue>4</issue><fpage>462</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1038/nbt1392</pub-id><pub-id pub-id-type="pmid">18362881</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Rosenfeld N, Aharonov R, Meiri E, et al. MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol. 2008;26(4):462&#8211;9.<pub-id pub-id-type="pmid">18362881</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nbt1392</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>White</surname><given-names>NM</given-names></name><name name-style="western"><surname>Bao</surname><given-names>TT</given-names></name><name name-style="western"><surname>Grigull</surname><given-names>J</given-names></name><etal/></person-group><article-title>MiRNA profiling for clear cell renal cell carcinoma: biomarker discovery and identification of potential controls and consequences of MiRNA dysregulation[J]</article-title><source>J Urol</source><year>2011</year><volume>186</volume><issue>3</issue><fpage>1077</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1016/j.juro.2011.04.110</pub-id><pub-id pub-id-type="pmid">21784468</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">White NM, Bao TT, Grigull J, et al. MiRNA profiling for clear cell renal cell carcinoma: biomarker discovery and identification of potential controls and consequences of MiRNA dysregulation. J Urol. 2011;186(3):1077&#8211;83.<pub-id pub-id-type="pmid">21784468</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.juro.2011.04.110</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><mixed-citation publication-type="other">Xiao Y, Yu D. Tumor microenvironment as a therapeutic target in cancer. Pharmacol Ther. 2021;221:107753.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pharmthera.2020.107753</pub-id><pub-id pub-id-type="pmcid">PMC8084948</pub-id><pub-id pub-id-type="pmid">33259885</pub-id></mixed-citation></ref><ref id="CR32"><label>32.</label><mixed-citation publication-type="other">Correia De Sousa M, Gjorgjieva M, Dolicka D et al. Deciphering miRNAs&#8217; Action through miRNA Editing. Int J Mol Sci. 2019;20(24).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms20246249</pub-id><pub-id pub-id-type="pmcid">PMC6941098</pub-id><pub-id pub-id-type="pmid">31835747</pub-id></mixed-citation></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fedorko</surname><given-names>M</given-names></name><name name-style="western"><surname>Pacik</surname><given-names>D</given-names></name><name name-style="western"><surname>Wasserbauer</surname><given-names>R</given-names></name><etal/></person-group><article-title>MicroRNAs in the pathogenesis of renal cell carcinoma and their diagnostic and prognostic utility as cancer biomarkers[J]</article-title><source>Int J Biol Markers</source><year>2016</year><volume>31</volume><issue>1</issue><fpage>e26</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.5301/jbm.5000174</pub-id><pub-id pub-id-type="pmid">26481440</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Fedorko M, Pacik D, Wasserbauer R, et al. MicroRNAs in the pathogenesis of renal cell carcinoma and their diagnostic and prognostic utility as cancer biomarkers. Int J Biol Mark. 2016;31(1):e26&#8211;37.<pub-id pub-id-type="pmid">26481440</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5301/jbm.5000174</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>R</given-names></name><name name-style="western"><surname>Li</surname><given-names>C</given-names></name><etal/></person-group><article-title>A microRNA-clinical prognosis model to predict the overall survival for kidney renal clear cell carcinoma[J]</article-title><source>Cancer Med</source><year>2021</year><volume>10</volume><issue>17</issue><fpage>6128</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1002/cam4.4148</pub-id><pub-id pub-id-type="pmid">34288551</pub-id><pub-id pub-id-type="pmcid">PMC8419758</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Zhan Y, Zhang R, Li C, et al. A microRNA-clinical prognosis model to predict the overall survival for kidney renal clear cell carcinoma. Cancer Med. 2021;10(17):6128&#8211;39.<pub-id pub-id-type="pmid">34288551</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cam4.4148</pub-id><pub-id pub-id-type="pmcid">PMC8419758</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vitruk</surname><given-names>Y</given-names></name><name name-style="western"><surname>Borikun</surname><given-names>T</given-names></name><name name-style="western"><surname>Rossylna</surname><given-names>O</given-names></name><etal/></person-group><article-title>EXPRESSION OF MiRNA AS PROGNOSTIC MARKERS OF RENAL CELL CARCINOMA COURSE[J]</article-title><source>Exp Oncol</source><year>2022</year><volume>44</volume><issue>2</issue><fpage>132</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.32471/exp-oncology.2312-8852.vol-44-no-2.17883</pub-id><pub-id pub-id-type="pmid">35964649</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Vitruk Y, Borikun T, Rossylna O, et al. Expression of mirna as prognostic markers of renal cell carcinoma course. Exp Oncol. 2022;44(2):132&#8211;6.<pub-id pub-id-type="pmid">35964649</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.32471/exp-oncology.2312-8852.vol-44-no-2.17883</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petillo</surname><given-names>D</given-names></name><name name-style="western"><surname>Kort</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Anema</surname><given-names>J</given-names></name><etal/></person-group><article-title>MicroRNA profiling of human kidney cancer subtypes[J]</article-title><source>Int J Oncol</source><year>2009</year><volume>35</volume><issue>1</issue><fpage>109</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.3892/ijo_00000318</pub-id><pub-id pub-id-type="pmid">19513557</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Petillo D, Kort EJ, Anema J, et al. MicroRNA profiling of human kidney cancer subtypes. Int J Oncol. 2009;35(1):109&#8211;14.<pub-id pub-id-type="pmid">19513557</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/ijo_00000318</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><mixed-citation publication-type="other">!!!. INVALID CITATION!!! [32&#8211;34].</mixed-citation></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>M</given-names></name><name name-style="western"><surname>Mo</surname><given-names>F</given-names></name><name name-style="western"><surname>Song</surname><given-names>X</given-names></name><etal/></person-group><article-title>Exosomal hsa-miR-21-5p is a biomarker for breast cancer diagnosis[J]</article-title><source>PeerJ</source><year>2021</year><volume>9</volume><fpage>e12147</fpage><pub-id pub-id-type="doi">10.7717/peerj.12147</pub-id><pub-id pub-id-type="pmid">34616615</pub-id><pub-id pub-id-type="pmcid">PMC8451442</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Liu M, Mo F, Song X, et al. Exosomal hsa-miR-21-5p is a biomarker for breast cancer diagnosis. PeerJ. 2021;9:e12147.<pub-id pub-id-type="pmid">34616615</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7717/peerj.12147</pub-id><pub-id pub-id-type="pmcid">PMC8451442</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><mixed-citation publication-type="other">Rodrigues PM, Afonso MB, Sim&#227;o AL, et al. miR-21-5p promotes NASH-related hepatocarcinogenesis. Liver Int. 2023.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/liv.15682</pub-id><pub-id pub-id-type="pmid">37534739</pub-id></mixed-citation></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>SK</given-names></name><name name-style="western"><surname>Park</surname><given-names>YS</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>JY</given-names></name><etal/></person-group><article-title>MiR 21-5p as a predictor of recurrence in young gastric cancer patients[J]</article-title><source>J Gastroenterol Hepatol</source><year>2016</year><volume>31</volume><issue>8</issue><fpage>1429</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1111/jgh.13300</pub-id><pub-id pub-id-type="pmid">26824898</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Park SK, Park YS, Ahn JY, et al. MiR 21-5p as a predictor of recurrence in young gastric cancer patients. J Gastroenterol Hepatol. 2016;31(8):1429&#8211;35.<pub-id pub-id-type="pmid">26824898</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jgh.13300</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><mixed-citation publication-type="other">Lao TD, Quang MT, Le T. a H. The Role of hsa-miR-21 and Its Target Genes Involved in Nasopharyngeal Carcinoma. Asian Pac J Cancer Prev. 2021;22(12):4075&#8211;4083.<pub-id pub-id-type="doi" assigning-authority="pmc">10.31557/APJCP.2021.22.12.4075</pub-id><pub-id pub-id-type="pmcid">PMC9080362</pub-id><pub-id pub-id-type="pmid">34967592</pub-id></mixed-citation></ref><ref id="CR42"><label>42.</label><mixed-citation publication-type="other">Lucarelli G, Lasorsa F, Milella M et al. Transcriptomic and proteo-metabolic determinants of the grading system in clear cell renal cell carcinoma. Urol Oncol. 2025.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.urolonc.2025.02.016</pub-id><pub-id pub-id-type="pmid">40082108</pub-id></mixed-citation></ref><ref id="CR43"><label>43.</label><mixed-citation publication-type="other">Milella M, Rutigliano M, Lasorsa F et al. The role of MUC1 in renal cell Carcinoma. Biomolecules. 2024;14(3).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biom14030315</pub-id><pub-id pub-id-type="pmcid">PMC10967890</pub-id><pub-id pub-id-type="pmid">38540735</pub-id></mixed-citation></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>JH</given-names></name><name name-style="western"><surname>Li</surname><given-names>YG</given-names></name><name name-style="western"><surname>Han</surname><given-names>ZP</given-names></name><etal/></person-group><article-title>The CircRNA-ACAP2/Hsa-miR-21-5p/ Tiam1 regulatory feedback circuit affects the proliferation, migration, and invasion of colon cancer SW480 Cells[J]</article-title><source>Cell Physiol Biochem</source><year>2018</year><volume>49</volume><issue>4</issue><fpage>1539</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1159/000493457</pub-id><pub-id pub-id-type="pmid">30212824</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">He JH, Li YG, Han ZP, et al. The CircRNA-ACAP2/Hsa-miR-21-5p/ Tiam1 regulatory feedback circuit affects the proliferation, migration, and invasion of colon cancer SW480 Cells. Cell Physiol Biochem. 2018;49(4):1539&#8211;50.<pub-id pub-id-type="pmid">30212824</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000493457</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><mixed-citation publication-type="other">Sequeira JP, Const&#226;ncio V, Salta S et al. LiKidMiRs: a ddPCR-based panel of 4 circulating MiRNAs for detection of renal cell carcinoma. Cancers (Basel). 2022;14(4).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers14040858</pub-id><pub-id pub-id-type="pmcid">PMC8869982</pub-id><pub-id pub-id-type="pmid">35205607</pub-id></mixed-citation></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Jin</surname><given-names>J</given-names></name><name name-style="western"><surname>Liang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>miR-21-5p/PRKCE axis implicated in immune infiltration and poor prognosis of kidney renal clear cell carcinoma[J]</article-title><source>Front Genet</source><year>2022</year><volume>13</volume><fpage>978840</fpage><pub-id pub-id-type="doi">10.3389/fgene.2022.978840</pub-id><pub-id pub-id-type="pmid">36186442</pub-id><pub-id pub-id-type="pmcid">PMC9516396</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Wang J, Jin J, Liang Y, et al. miR-21-5p/PRKCE axis implicated in immune infiltration and poor prognosis of kidney renal clear cell carcinoma. Front Genet. 2022;13:978840.<pub-id pub-id-type="pmid">36186442</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fgene.2022.978840</pub-id><pub-id pub-id-type="pmcid">PMC9516396</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petrozza</surname><given-names>V</given-names></name><name name-style="western"><surname>Carbone</surname><given-names>A</given-names></name><name name-style="western"><surname>Bellissimo</surname><given-names>T</given-names></name><etal/></person-group><article-title>Oncogenic MicroRNAs characterization in clear cell renal cell Carcinoma[J]</article-title><source>Int J Mol Sci</source><year>2015</year><volume>16</volume><issue>12</issue><fpage>29219</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.3390/ijms161226160</pub-id><pub-id pub-id-type="pmid">26670229</pub-id><pub-id pub-id-type="pmcid">PMC4691105</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Petrozza V, Carbone A, Bellissimo T, et al. Oncogenic MicroRNAs characterization in clear cell renal cell Carcinoma. Int J Mol Sci. 2015;16(12):29219&#8211;25.<pub-id pub-id-type="pmid">26670229</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms161226160</pub-id><pub-id pub-id-type="pmcid">PMC4691105</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T</given-names></name><name name-style="western"><surname>Yao</surname><given-names>ZY</given-names></name><etal/></person-group><article-title>MicroRNA related prognosis biomarkers from high throughput sequencing data of kidney renal clear cell carcinoma[J]</article-title><source>BMC Med Genomics</source><year>2021</year><volume>14</volume><issue>1</issue><fpage>72</fpage><pub-id pub-id-type="doi">10.1186/s12920-021-00932-z</pub-id><pub-id pub-id-type="pmid">33750388</pub-id><pub-id pub-id-type="pmcid">PMC7941961</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Huang M, Zhang T, Yao ZY, et al. MicroRNA related prognosis biomarkers from high throughput sequencing data of kidney renal clear cell carcinoma BMC Med Genom. 2021;14(1):72.<pub-id pub-id-type="pmid">33750388</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12920-021-00932-z</pub-id><pub-id pub-id-type="pmcid">PMC7941961</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>M</given-names></name><name name-style="western"><surname>Lv</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Identification and validation of a four-miRNA (miRNA-21-5p, miRNA-9-5p, miR-149-5p, and miRNA-30b-5p) prognosis signature in clear cell renal cell carcinoma[J]</article-title><source>Cancer Manag Res</source><year>2018</year><volume>10</volume><fpage>5759</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.2147/CMAR.S187109</pub-id><pub-id pub-id-type="pmid">30532596</pub-id><pub-id pub-id-type="pmcid">PMC6245347</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Xie M, Lv Y, Liu Z, et al. Identification and validation of a four-miRNA (miRNA-21-5p, miRNA-9-5p, miR-149-5p, and miRNA-30b-5p) prognosis signature in clear cell renal cell carcinoma. Cancer Manag Res. 2018;10:5759&#8211;66.<pub-id pub-id-type="pmid">30532596</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/CMAR.S187109</pub-id><pub-id pub-id-type="pmcid">PMC6245347</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>D</given-names></name><etal/></person-group><article-title>Calcium homeostasis and cancer: insights from Endoplasmic reticulum-centered organelle communications[J]</article-title><source>Trends Cell Biol</source><year>2023</year><volume>33</volume><issue>4</issue><fpage>312</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2022.07.004</pub-id><pub-id pub-id-type="pmid">35915027</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Zheng S, Wang X, Zhao D, et al. Calcium homeostasis and cancer: insights from Endoplasmic reticulum-centered organelle communications. Trends Cell Biol. 2023;33(4):312&#8211;23.<pub-id pub-id-type="pmid">35915027</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tcb.2022.07.004</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kovesdy</surname><given-names>CP</given-names></name><name name-style="western"><surname>Furth</surname><given-names>S</given-names></name><name name-style="western"><surname>Zoccali</surname><given-names>C</given-names></name></person-group><article-title>Obesity and kidney disease: hidden consequences of the epidemic[J]</article-title><source>Physiol Int</source><year>2017</year><volume>104</volume><issue>1</issue><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1556/2060.104.2017.1.9</pub-id><pub-id pub-id-type="pmid">28361575</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Kovesdy CP, Furth S, Zoccali C. Obesity and kidney disease: hidden consequences of the epidemic. Physiol Int. 2017;104(1):1&#8211;14.<pub-id pub-id-type="pmid">28361575</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1556/2060.104.2017.1.9</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lucarelli</surname><given-names>G</given-names></name><name name-style="western"><surname>Loizzo</surname><given-names>D</given-names></name><name name-style="western"><surname>Franzin</surname><given-names>R</given-names></name><etal/></person-group><article-title>Metabolomic insights into pathophysiological mechanisms and biomarker discovery in clear cell renal cell carcinoma[J]</article-title><source>Expert Rev Mol Diagn</source><year>2019</year><volume>19</volume><issue>5</issue><fpage>397</fpage><lpage>407</lpage><pub-id pub-id-type="doi">10.1080/14737159.2019.1607729</pub-id><pub-id pub-id-type="pmid">30983433</pub-id></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Lucarelli G, Loizzo D, Franzin R, et al. Metabolomic insights into pathophysiological mechanisms and biomarker discovery in clear cell renal cell carcinoma. Expert Rev Mol Diagn. 2019;19(5):397&#8211;407.<pub-id pub-id-type="pmid">30983433</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/14737159.2019.1607729</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bianchi</surname><given-names>C</given-names></name><name name-style="western"><surname>Meregalli</surname><given-names>C</given-names></name><name name-style="western"><surname>Bombelli</surname><given-names>S</given-names></name><etal/></person-group><article-title>The glucose and lipid metabolism reprogramming is grade-dependent in clear cell renal cell carcinoma primary cultures and is targetable to modulate cell viability and proliferation[J]</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><issue>69</issue><fpage>113502</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.23056</pub-id><pub-id pub-id-type="pmid">29371925</pub-id><pub-id pub-id-type="pmcid">PMC5768342</pub-id></element-citation><mixed-citation id="mc-CR53" publication-type="journal">Bianchi C, Meregalli C, Bombelli S, et al. The glucose and lipid metabolism reprogramming is grade-dependent in clear cell renal cell carcinoma primary cultures and is targetable to modulate cell viability and proliferation. Oncotarget. 2017;8(69):113502&#8211;15.<pub-id pub-id-type="pmid">29371925</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/oncotarget.23056</pub-id><pub-id pub-id-type="pmcid">PMC5768342</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Lu</surname><given-names>S</given-names></name><etal/></person-group><article-title>Metabolic reprogramming of clear cell renal cell carcinoma[J]</article-title><source>Front Endocrinol (Lausanne)</source><year>2023</year><volume>14</volume><fpage>1195500</fpage><pub-id pub-id-type="doi">10.3389/fendo.2023.1195500</pub-id><pub-id pub-id-type="pmid">37347113</pub-id><pub-id pub-id-type="pmcid">PMC10280292</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Zhu H, Wang X, Lu S, et al. Metabolic reprogramming of clear cell renal cell carcinoma[J]. Front Endocrinol (Lausanne). 2023;14:1195500.<pub-id pub-id-type="pmid">37347113</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fendo.2023.1195500</pub-id><pub-id pub-id-type="pmcid">PMC10280292</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qi</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q</given-names></name><name name-style="western"><surname>Che</surname><given-names>X</given-names></name><etal/></person-group><article-title>The uniqueness of clear cell renal cell carcinoma: summary of the process and abnormality of glucose metabolism and lipid metabolism in ccRCC[J]</article-title><source>Front Oncol</source><year>2021</year><volume>11</volume><fpage>727778</fpage><pub-id pub-id-type="doi">10.3389/fonc.2021.727778</pub-id><pub-id pub-id-type="pmid">34604067</pub-id><pub-id pub-id-type="pmcid">PMC8479096</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Qi X, Li Q, Che X, et al. The uniqueness of clear cell renal cell carcinoma: summary of the process and abnormality of glucose metabolism and lipid metabolism in ccRCC. Front Oncol. 2021;11:727778.<pub-id pub-id-type="pmid">34604067</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2021.727778</pub-id><pub-id pub-id-type="pmcid">PMC8479096</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><mixed-citation publication-type="other">Ragone R, Sallustio F, Piccinonna S et al. Renal cell carcinoma: A study through NMR-Based metabolomics combined with Transcriptomics. Diseases. 2016;4(1).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/diseases4010007</pub-id><pub-id pub-id-type="pmcid">PMC5456302</pub-id><pub-id pub-id-type="pmid">28933387</pub-id></mixed-citation></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bombelli</surname><given-names>S</given-names></name><name name-style="western"><surname>Torsello</surname><given-names>B</given-names></name><name name-style="western"><surname>De Marco</surname><given-names>S</given-names></name><etal/></person-group><article-title>36-kDa Annexin A3 isoform negatively modulates lipid storage in clear cell renal cell carcinoma cells[J]</article-title><source>Am J Pathol</source><year>2020</year><volume>190</volume><issue>11</issue><fpage>2317</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1016/j.ajpath.2020.08.008</pub-id><pub-id pub-id-type="pmid">32861643</pub-id></element-citation><mixed-citation id="mc-CR57" publication-type="journal">Bombelli S, Torsello B, De Marco S, et al. 36-kDa Annexin A3 isoform negatively modulates lipid storage in clear cell renal cell carcinoma cells. Am J Pathol. 2020;190(11):2317&#8211;26.<pub-id pub-id-type="pmid">32861643</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajpath.2020.08.008</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lucarelli</surname><given-names>G</given-names></name><name name-style="western"><surname>Galleggiante</surname><given-names>V</given-names></name><name name-style="western"><surname>Rutigliano</surname><given-names>M</given-names></name><etal/></person-group><article-title>Metabolomic profile of Glycolysis and the Pentose phosphate pathway identifies the central role of glucose-6-phosphate dehydrogenase in clear cell-renal cell carcinoma[J]</article-title><source>Oncotarget</source><year>2015</year><volume>6</volume><issue>15</issue><fpage>13371</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.3823</pub-id><pub-id pub-id-type="pmid">25945836</pub-id><pub-id pub-id-type="pmcid">PMC4537021</pub-id></element-citation><mixed-citation id="mc-CR58" publication-type="journal">Lucarelli G, Galleggiante V, Rutigliano M, et al. Metabolomic profile of Glycolysis and the Pentose phosphate pathway identifies the central role of glucose-6-phosphate dehydrogenase in clear cell-renal cell carcinoma. Oncotarget. 2015;6(15):13371&#8211;86.<pub-id pub-id-type="pmid">25945836</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/oncotarget.3823</pub-id><pub-id pub-id-type="pmcid">PMC4537021</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nasci</surname><given-names>VL</given-names></name><name name-style="western"><surname>Chuppa</surname><given-names>S</given-names></name><name name-style="western"><surname>Griswold</surname><given-names>L</given-names></name><etal/></person-group><article-title>miR-21-5p regulates mitochondrial respiration and lipid content in H9C2 cells[J]</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2019</year><volume>316</volume><issue>3</issue><fpage>H710</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.00538.2017</pub-id><pub-id pub-id-type="pmid">30657727</pub-id><pub-id pub-id-type="pmcid">PMC6459316</pub-id></element-citation><mixed-citation id="mc-CR59" publication-type="journal">Nasci VL, Chuppa S, Griswold L, et al. miR-21-5p regulates mitochondrial respiration and lipid content in H9C2 cells. Am J Physiol Heart Circ Physiol. 2019;316(3):H710&#8211;21.<pub-id pub-id-type="pmid">30657727</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/ajpheart.00538.2017</pub-id><pub-id pub-id-type="pmcid">PMC6459316</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vuong</surname><given-names>L</given-names></name><name name-style="western"><surname>Kotecha</surname><given-names>RR</given-names></name><name name-style="western"><surname>Voss</surname><given-names>MH</given-names></name><etal/></person-group><article-title>Tumor microenvironment dynamics in Clear-Cell renal cell Carcinoma[J]</article-title><source>Cancer Discov</source><year>2019</year><volume>9</volume><issue>10</issue><fpage>1349</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-19-0499</pub-id><pub-id pub-id-type="pmid">31527133</pub-id><pub-id pub-id-type="pmcid">PMC6774890</pub-id></element-citation><mixed-citation id="mc-CR60" publication-type="journal">Vuong L, Kotecha RR, Voss MH, et al. Tumor microenvironment dynamics in Clear-Cell renal cell Carcinoma. Cancer Discov. 2019;9(10):1349&#8211;57.<pub-id pub-id-type="pmid">31527133</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/2159-8290.CD-19-0499</pub-id><pub-id pub-id-type="pmcid">PMC6774890</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><mixed-citation publication-type="other">Tamma R, Rutigliano M, Lucarelli G et al. Microvascular density, macrophages, and mast cells in human clear cell renal carcinoma with and without bevacizumab treatment. Urol Oncol. 2019;37(6):355.e11&#8211;355.e19.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.urolonc.2019.01.025</pub-id><pub-id pub-id-type="pmid">30738745</pub-id></mixed-citation></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yin</surname><given-names>C</given-names></name><name name-style="western"><surname>Geng</surname><given-names>L</given-names></name><etal/></person-group><article-title>Immune infiltration landscape in clear cell renal cell carcinoma Implications[J]</article-title><source>Front Oncol</source><year>2020</year><volume>10</volume><fpage>491621</fpage><pub-id pub-id-type="doi">10.3389/fonc.2020.491621</pub-id><pub-id pub-id-type="pmid">33665156</pub-id><pub-id pub-id-type="pmcid">PMC7923891</pub-id></element-citation><mixed-citation id="mc-CR62" publication-type="journal">Wang Y, Yin C, Geng L, et al. Immune infiltration landscape in clear cell renal cell carcinoma Implications. Front Oncol. 2020;10:491621.<pub-id pub-id-type="pmid">33665156</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2020.491621</pub-id><pub-id pub-id-type="pmcid">PMC7923891</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><mixed-citation publication-type="other">Ghini V, Laera L, Fantechi B et al. Metabolomics to assess response to immune checkpoint inhibitors in patients with Non-Small-Cell lung Cancer. Cancers (Basel). 2020;12(12).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers12123574</pub-id><pub-id pub-id-type="pmcid">PMC7760033</pub-id><pub-id pub-id-type="pmid">33265926</pub-id></mixed-citation></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Netti</surname><given-names>GS</given-names></name><name name-style="western"><surname>Lucarelli</surname><given-names>G</given-names></name><name name-style="western"><surname>Spadaccino</surname><given-names>F</given-names></name><etal/></person-group><article-title>PTX3 modulates the immunoflogosis in tumor microenvironment and is a prognostic factor for patients with clear cell renal cell carcinoma[J]</article-title><source>Aging</source><year>2020</year><volume>12</volume><issue>8</issue><fpage>7585</fpage><lpage>602</lpage><pub-id pub-id-type="doi">10.18632/aging.103169</pub-id><pub-id pub-id-type="pmid">32345771</pub-id><pub-id pub-id-type="pmcid">PMC7202504</pub-id></element-citation><mixed-citation id="mc-CR64" publication-type="journal">Netti GS, Lucarelli G, Spadaccino F, et al. PTX3 modulates the immunoflogosis in tumor microenvironment and is a prognostic factor for patients with clear cell renal cell carcinoma. Aging. 2020;12(8):7585&#8211;602.<pub-id pub-id-type="pmid">32345771</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/aging.103169</pub-id><pub-id pub-id-type="pmcid">PMC7202504</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><mixed-citation publication-type="other">Lucarelli G, Netti GS, Rutigliano M et al. MUC1 expression affects the immunoflogosis in renal cell carcinoma microenvironment through complement system activation and immune infiltrate Modulation. Int J Mol Sci. 2023;24(5).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms24054814</pub-id><pub-id pub-id-type="pmcid">PMC10003656</pub-id><pub-id pub-id-type="pmid">36902242</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>